<?xml version="1.0" encoding="utf-8"?>
<add>
	<doc>
		<field name="docid">BR-TU.19771</field>
		<field name="filename">3189_SantosFilho_HiltonOliveirados_D.pdf</field>
		<field name="filetype">PDF</field>
		<field name="text">
 

 
 
 
 
 
 
 
 

      
 
 
 

 

HILTON OLIVEIRA DOS SANTOS FILHO 

 
 
 

ESTUDO CLÍNICO FASE I DE CARBONATO DE 
LODENAFILA, UM NOVO TIPO DE INIBIDOR DE 

FOSFODIESTERASE 5 (PDE5), EM VOLUNTÁRIOS 
SAUDÁVEIS DO SEXO MASCULINO. 

 
 
A PHASE I CLINICAL TRIAL OF LODENAFIL CARBONATE, A 
NEW PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITOR, IN 

HEALTHY MALE VOLUNTEERS. 

 
 
 
 
 

 
 
 
 
 
 
 

 
 
 

Campinas 
2013 

 
 
 
 
 



 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ii 



 

 
 
 

 
 
 
UNIVERSIDADE ESTADUAL DE CAMPINAS 

Faculdade de Ciências Médicas 
 
 
 

 
HILTON OLIVEIRA DOS SANTOS FILHO 

 
ESTUDO CLÍNICO FASE I DE CARBONATO DE LODENAFILA, UM 
NOVO TIPO DE INIBIDOR DE  FOSFODIESTERASE 5 (PDE5), EM 

VOLUNTÁRIOS SAUDÁVEIS DO SEXO MASCULINO 

  
 

Orientador (a) / Supervisor: Prof. Dr. Gilberto De Nucci 

 

 

A PHASE I CLINICAL TRIAL OF LODENAFIL CARBONATE, A NEW 
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITOR, IN HEALTHY 

MALE VOLUNTEERS 

 
 

 
Tese de Doutorado apresentada ao Programa de Pós-Graduação em 

Clínica Médica da Faculdade de Ciências Médicas da Universidade de Campinas 
para obtenção de título de Doutor em Clínica Médica, área de concentração Clínica 
Médica. 
 

Doctoral Thesis presented to the Internal Medicine Posgraduate 
Program of the Faculty of Medical Sciences, State University of Campinas, for 
obtainment of the Ph.D. degree in Internal Medicine/Medical Sciences, 
specialization in Internal Medicine. 

 
 

 
ESTE EXEMPLAR CORRESPONDE À VERSÃO FINAL DA 
TESE DEFENDIDA PELO ALUNO HILTON OLIVEIRA DOS 
SANTOS FILHO E ORIENTADO PELO PROF. DR. 
GILBERTO DE NUCCI. 
 
 
Assinatura do Orientador 
 
 

 
 
 

 
Campinas  

2013 



 

iv 

FICHA CATALOGRÁFICA ELABORADA POR 
MARISTELLA SOARES DOS SANTOS – CRB8/8402  

BIBLIOTECA DA FACULDADE DE CIÊNCIAS MÉDICAS  
UNICAMP 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
Informações para Biblioteca Digital 
 
Título em inglês: A phase I clinical trial of lodenafil carbonate, a new 
phosphodiesterase type 5 (PDE5) inhibitor, in healthy male volunteers. 
Palavras-chave em inglês: 
Erectile dysfunction 
Phosphodiesterase type 5 (PDE5) inhibitors 
Pharmacokinetics 
Safety 
Área de concentração: Clínica Médica 
Titulação: Doutor em Clínica Médica 
Banca examinadora:  
Gilberto De Nucci [Orientador] 
Ubirajara Ferreira 
Sara Teresinha Olalla Saad 
Manoel Odorico de Moares Filho 
Roberto Soares de Moura 
Data da defesa: 13-05-2013 
Programa de Pós-Graduação: Clínica Médica 
 

 
 Santos Filho, Hilton Oliveira dos, 1956- 
 S237e    Estudo clínico fase I de carbonato de lodenafila, um 

novo tipo de inibidor de  fosfodiesterase 5 (PDE5), em 
voluntários saudáveis do sexo masculino / Hilton Oliveira 
dos Santos Filho. -- Campinas, SP : [s.n.], 2013. 

 
    Orientador : Gilberto De Nucci. 
    Tese (Doutorado) - Universidade Estadual de 

Campinas, Faculdade de Ciências Médicas.  
 
    1. Disfunção erétil. 2. Inibidores da fosfodiesterase 

tipo 5. 3. Farmacocinética. 4. Segurança. I. De Nucci, 
Gilberto, 1958-. II. Universidade Estadual de Campinas. 
Faculdade de Ciências Médicas. III. Título.  

 





 
 

DEDICATÓRIA 

 

 

 

 

 

 

Aos meus pais, Hilton e Dalva:  

De quem Deus me deu a honra de ser filho, responsáveis por minha 

formação ética e profissional, meus grandes exemplos  

de vida.   Meu amor por vocês é infinito e eterno. 

 

A minha esposa Fátima, meus filhos Carla e Bruno:  

Razões de minha vida, e a quem devo muito do que consegui até o momento. 

Meu amor incondicional e gratidão. 

 

vi 

 



 
 

AGRADECIMENTOS 

 

 

 

 

 

 

 

Agradeço a minha esposa, Fátima, pela enorme paciência, amor incondicional e companheirismo. 

Aos meus pais, Hilton e Dalva, pelo apoio em todos os meus projetos, por mais ousados que tenham 

sido. Sempre me estimularam a ir mais adiante e a acreditaram em meu potencial.  

Em especial ao orientador Prof. Dr. Gilberto De Nucci pela confiança; amizade, oportunidade de 

aprendizado que tive a honra de receber.  Sua experiência e seu conhecimento serão reconhecidos 

eternamente por toda a comunidade acadêmica nacional e internacional.  

É uma honra imensa poder ter este grande cientista e pessoa excepcional como meu orientador. 

Em especial ao Dr. Márcio Falci, pela grande amizade, confiança,  

aprendizado profissional e de vida durante vários anos. 

Agradeço a todos que direta ou indiretamente contribuíram para a realização desse trabalho. 

Especialmente, aos que participam ou participaram dos grupos de pesquisa do  

Prof. Dr. Gilberto De Nucci. 

A TODOS, O MEU MAIS SINCERO MUITO OBRIGADO! 

 

vii 



 
 

Carbonato de Lodenafila é um novo tipo de inibidor de fosfodiesterase 5 (PDE5) utilizado no 

tratamento da disfunção erétil. O presente estudo foi realizado para avaliar a segurança, 

tolerabilidade e farmacocinética do carbonato de lodenafila após a administração de doses 

orais únicas ascendentes (de 1 a 100 mg) a voluntários saudáveis do sexo masculino (n = 33). 

O estudo foi um estudo clínico fase I, aberto, de escalonamento de dose, utilizando a 

administração de doses orais únicas de carbonato de lodenafila. Carbonato de Lodenafila foi 

administrado sequencialmente escalonado em doses únicas de 1 mg a 100 mg com um 

período sem uso do medicamento (washout) de pelo menos 1 semana, entre cada dose. A 

progressão para a próxima dose foi permitida se após a avaliação dos exames clínicos, 

laboratoriais e Monitorização Ambulatorial da Pressão Arterial (MAPA), não demonstrassem 

alterações e eventos adversos sem relevância clínica. As amostras de sangue foram coletadas 

na pré-dose e em intervalos determinados e 24 horas após a administração. As amostras de 

plasma para a mensuração de carbonato lodenafila e lodenafila foram analisadas por 

cromatografia líquida acoplada à espectrometria de massa. Não foram observados eventos 

adversos graves, e nenhum dos voluntários abandonou o estudo devido à intolerância. As 

medições do MAPA, exames clínicos e laboratoriais e ECG não revelaram alterações 

significativas mesmo em doses mais elevadas. Carbonato Lodenafila não foi detectado em 

qualquer amostra, indicando que ele atua como um pró-droga. Os parâmetros 

farmacocinéticos médios de lodenafila para tmax e t1 / 2 foram 1,6 (± 0,4) horas e 3,3 (± 1,1) 

horas, respectivamente. Este estudo demonstrou que o carbonato de lodenafila é bem tolerado 

e apresentou um bom perfil de segurança em voluntários saudáveis do sexo masculino. 

 Palavras-chave: inibidores da fosfodiesterase tipo 5 (PDE5), farmacocinética, segurança. 

Resumo 

viii 



 
 

Lodenafil carbonate is a new phosphodiesterase type 5 (PDE5) inhibitor used in treatment of 

erectile dysfunction. The present study was conducted to evaluate the safety, tolerability, and 

pharmacokinetics of lodenafil carbonate after administering ascending (1 to 100 mg) single 

oral doses to healthy male volunteers (n=33). The study was an open-label, dose-escalation, 

phase I clinical trial involving the administration of single oral doses of lodenafil carbonate. 

Lodenafil carbonate was administered sequentially, escalating in single doses of 1 mg to 100 

mg with a washout period of at least 1 week between each dose. The progression to the next 

dose was allowed after clinical and laboratory exams, Ambulatory Monitoring of Arterial 

Pressure (AMAP) without relevant clinical modifications and adverse events without clinical 

relevancy. Blood samples were collected at pre-dose, determined intervals and 24h post-

dosing. Plasma samples for measurement of lodenafil carbonate and lodenafil were analyzed 

by liquid chromatography coupled to tandem mass spectrometry. No serious adverse events 

were observed, and none of the subjects discontinued the study due to intolerance. The 

AMAP measurements, clinical and laboratory exams and ECG revealed no significant 

changes even at higher doses. Lodenafil carbonate was not detected in any samples, indicating 

that it acts as a pro-drug. The mean lodenafil pharmacokinetic parameters for tmax and t1/2 

were 1.6 (±0.4) hr and 3.3 (±1.1) hr, respectively. This study demonstrated that lodenafil 

carbonate was well tolerated and showed a good safety profile in healthy male volunteers. 

Key words: phosphodiesterase type 5 (PDE5) inhibitor, pharmacokinetics, safety 

 

 

Abstract 

ix 

 



 
 

Lista de abreviaturas 

AMPc: Monofosfato cíclico de adenosina 

ANVISA: Agência Nacional de Vigilância Sanitária 

AVC: Acidente vascular cerebral  

BNDES: Banco Nacional do Desenvolvimento Econômico e Social 

CEMIB: Centro Multidisciplinar para Investigação Biológica na Área da Ciência em Animais 
de Laboratório 

CTC: Common toxicity criteria - critério comum de toxicidade 

DE: Disfunção erétil  

DL50: dose letal 50% 

DLT: dose-limiting toxicity - dose limite de toxicidade  

EC50: Efeito máximo 50% - concentração de droga necessária para produzir 50% do efeito 
máximo 

FINEP: Financiadora de Estudos e Projetos 

FOB: Functional observation battery - bateria de observação funcional 

GMPc: Monofosfato cíclico de guanosina 

HED: Human equivalent dose - dose equivalente humana 

IIEF: International Index for Erectile Function- Índice internacional de Função Erétil 

IIEF5: Índice Internacional de Função Erétil-5  

MAPA: Monitorização ambulatorial da pressão arterial  

MRSD: Maximum recommended starting dose - dose máxima inicial 

MTD: Maximum tolerable dosage - dose máxima tolerada 

NOAEL: No observed adverse effect level – nível de efeito adverso não observado 

P&amp;amp;D: Pesquisa e Desenvolvimento  

PDE5: inibidores da fosfodiesterase tipo 5  

pEC50: antilog da concentração de droga necessária para produzir 50% do efeito máximo 

TRPN: Tumescência e rigidez peniana noturna  

UNICAMP: Universidade Estadual de Campinas 

 

 

x 



 
 

Lista de tabelas 

Table 1: Treatment scheme with lodenafil in 1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 

10 mg, 20 mg, 30 g, 50 mg, 80 mg and 100 mg in healthy male 

volunteers……………………………………………………………………… 

 
 
 
 
 

46 

Table 2: Accuracy and precision data for lodenafil carbonate and lodenafil 

from the pre-study validation in human 

plasma……………………………………................................................ 

 
 
 
 
 

47 

Table 3: Mean pharmacokinetic parameters obtained from volunteers after 

administration of lodenafil carbonate formulation (1 mg, 2 mg, 3 mg, 5 mg, 8 

mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg and 100 mg) in 33 healthy 

volunteers……………………………………………………………………… 

Table 4: Laboratory tests in healthy male volunteers after administration of 
lodenafil carbonate…………………………………………………………… 
 

 
 
 
 
 
 
 
 

48 
 
 
 

49 
 

Table 5: Mean sitting systolic and diastolic blood pressures and mean heart 

rates after lodenafil carbonate administration ……………………………… 

 
 

 
50 

 

 

 

 

 

 

xi 

 



 
 

Lista de figuras 

 

Figure 1: The mean lodenafil plasma concentrations vs. time profiles after a 
single oral dose (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 
80 mg, 100 mg) tablet formulation of lodenafil carbonate in male volunteers... 

 
 
51 

 
Figure 2: Mean sitting systolic and diastolic blood pressures and sitting heart 
rates after lodenafil carbonate administration………………………………….. 

 
 
52 

 

 

 

 

 

 

 

 

 

 

 

 

 

xii 

 

 



 
 

 

SUMÁRIO 

Resumo................................................................................................................. viii 
Abstract................................................................................................................. ix 
Lista de abreviaturas............................................................................................. x 
Lista de tabelas..................................................................................................... xi 
Lista de figuras...................................................................................................... xii 
1. Introdução geral............................................................................................... 14 
     1.1 Fisiologia e fisiopatologia da disfunção erétil......................................... 16 
     1.2 Diagnóstico da disfunção erétil.................................................................. 17 
     1.3 Tratamento da disfunção erétil.................................................................. 19 
     1.3.1. Tratamento de primeira linha................................................................ 19 
     1.3.2. Tratamento de segunda linha............................................................... 21 
     1.3.3 Tratamento de terceira linha (prótese peniana) .................................... 21 
     1.4 O desenvolvimento de um novo medicamento......................................... 22 
     1.4.1 Estudos Clínicos: fase I, II, III e IV....................................................... 24 
     1.5 Estudos preliminares com o carbonato de lodenafila................................ 27 
     1.5.1 Estudos pré-clínicos de toxicidade.......................................................... 29 
     1.6 Objetivo. ................................................................................................... 30 
2. Capítulo I........................................................................................................... 31 
3. Discussão.......................................................................................................... 53 
4. Conclusão.......................................................................................................... 55 
5. Referências bibliográficas................................................................................. 56 
Anexos................................................................................................................... 59 

 

 

 

 

 

 

 



 

14 
 

1. Introdução Geral 

 

A disfunção erétil (DE) é uma condição clínica definida como a incapacidade 

persistente de obter ou manter uma ereção suficiente para permitir um desempenho sexual 

satisfatório (1, 2). 

É considerada por muitos como uma doença, tendo em vista seu amplo espectro de dano 

ao indivíduo. Apesar de benigna, acomete o indivíduo e seus familiares tendo em vista que 

tanto a saúde física como a psicossocial se encontram afetada (3). 

Em relação à sua epidemiologia, a literatura demonstra dados de incidência e 

prevalência com variações amplas. Este fato deve-se provavelmente a diversos fatores, como 

diferentes metodologias utilizadas, idade e condição socioeconômica das populações 

estudadas.  

No entanto, uma revisão dos estudos epidemiológicos, realizada em 2003, sugere que a 

DE de intensidade moderada a severa, afeta 5% a 20% dos homens (4). 

Estudo realizado na população brasileira demonstrou que 25 milhões de homens com 

mais de 18 anos apresentam algum grau de DE e aproximadamente 11 milhões tenham 

disfunção erétil moderada ou severa. A incidência de DE na população brasileira foi de 65,6 

casos por 1.000 pessoas /ano. Com a projeção de um milhão de novos casos anualmente 

demonstra que a DE deve ser considerada um problema de saúde pública (5,6).  

Como será abordado em maiores detalhes a seguir, o desenvolvimento de um novo 

fármaco é extremamente complexo e com taxa de sucesso baixa, mesmo em países onde este 

procedimento já é muito bem conhecido e executado. 



 

15 
 

O medicamento abordado neste trabalho foi desenvolvido, patenteado e registrado na 

Agência Nacional de Vigilância Sanitária (ANVISA) para comercialização, integralmente no 

Brasil, processo pioneiro em nosso país.  

A denominada inovação colaborativa foi utilizada com muita propriedade durante todo 

o processo de desenvolvimento. A integração entre a universidade, indústria e órgãos 

governamentais, foi determinante para que o projeto fosse executado e o resultado esperado, 

alcançado. Um medicamento inovador com desenvolvimento inteiramente brasileiro. 

Podemos afirmar, sem receio de cometermos excessos, que a universidade, indústria, 

governo e principalmente a população brasileira podem se orgulhar deste projeto, exemplo a 

ser seguido por todos os setores envolvidos na pesquisa e desenvolvimento (P&amp;amp;D) brasileiro.  

 



 

 16  
 

1.1 Fisiologia e fisiopatologia da Disfunção Erétil  

A ereção é resultado de uma complexa integração de funções neurais, hormonais e 

vasculares.  

Resumidamente, uma ereção ocorre quando o fluxo de sangue para o pênis excede o 

fluxo para fora do pênis, conforme detalhado a seguir.  

As artérias cavernosas fornecem sangue para o corpo cavernoso do pênis (através da 

artéria pudenda), enquanto as veias emissárias  drenam o corpo cavernoso (para a veia 

pudenda interna). Durante a ereção, as fibras da musculatura lisa  do corpo cavernoso se 

encontram relaxadas, diminuindo a resistência ao fluxo arterial para o corpo cavernoso e  

consequente  expansão dos sinusoides nele contidos.  Esta distensão causa compressão 

mecânica sobre as veias emissárias , o que impede a sua capacidade para drenar o sangue 

resultando em rigidez peniana. Durante a ereção, o pênis atua como um capacitor, 

acumulando sangue sob pressão devido ao relaxamento dos corpos cavernosos (7). 

O fluxo sanguíneo do pênis é controlado pelo centro da ereção autonômica, através dos 

nervos parassimpáticos (S2-S4), simpáticos (T12-L2) e plexo pélvico incluindo o nervo 

cavernoso, que inerva as artérias e musculatura lisa trabecular do corpo cavernoso.   

Apesar de existir uma grande sinergia entre eles, dois mecanismos podem desencadear 

as alterações vasculares envolvidas na ereção peniana: psicogênicas e reflexogênicas.  

As psicogênicas agem através de estímulos como, som, odor, visão e tato. As 

reflexogênicas através da estimulação peniana direta.  

Nos dois mecanismos neurotransmissores são envolvidos na ereção e detumescência, 

entre eles a dopamina e noradrenalina. 



 

 17  
 

Os hormônios androgênicos atuam modulando a libido e comportamento sexual. A 

testosterona aumenta o interesse e a frequência dos atos sexuais, no entanto não afeta as 

ereções reflexogênicas e psicogênicos.   

O neurotransmissor óxido nítrico, um dos mais importantes sinalizadores intra e 

extracelular é, em última análise, o responsável pelo mecanismo de ereção e relaxamento 

peniano. 

Este sinalizador se difunde através da membrana do músculo liso e ativa a guanilato 

ciclase para produzir o monofosfato cíclico de guanosina (GMPc) que desencadeia uma 

cascata de reações bioquímicas levando a uma alteração da permeabilidade dos canais iônicos 

de cálcio e potássio. Esta alteração diminui o cálcio intracelular promovendo o relaxamento 

do músculo liso, aumento do fluxo sanguíneo e consequentemente ereção peniana. 

As enzimas fosfodiesterases, principalmente a isoforma 5 (PDE5), regulam o 

mecanismo descrito acima catalisando a reação inversa das guanilato ciclases e inativando o 

GMPc através da sua transformação em GMP (8). 

Pelo menos 11 famílias de PDEs foram descritas em mamíferos, mas como alguns tipos 

estão associados a mais de um gene e podem diferir quanto à afinidade e especificidade pelos 

possíveis substratos (GMPc ou AMPc), o resultado é pelo menos 50 isotipos de PDEs. A 

PDE5 é a fosfodiesterase predominante no corpo cavernoso do homem (9,10). 

 

1.2 Diagnóstico da Disfunção Erétil  

Conforme já descrito, a  ereção é um fenômeno neurovascular sob controle hormonal.  

A DE compartilha fatores de risco com as doença cardiovascular como  sedentarismo, 

obesidade, tabagismo, hipercolesterolemia e  síndrome metabólica. Este fato é importante pois 

o conhecimento destes fatores de risco tem  impacto importante no tratamento da DE (11, 12).  



 

 18  
 

A etiologia da DE é dividada em: vasculogênica, neurogênica, hormonal, anatômica, 

medicamentosa, ou psicogênica. É comum mais de uma etiologia estar presente em um 

mesmo paciente. Por este motivo, a classificação que inclui o termo mista, se aproxima muito 

da realidade clínica da doença.  

As vasculogênicas estão relacionadas às doenças cardiovasculares, hipertensão, 

diabetes mellitus, hiperlipidemia, tabagismo, cirurgias de grande porte ou radioterapia (pélvis 

ou retroperitônio). 

As neurogênicas são subdivididas em: causas centrais: como por exemplo, a esclerose 

múltipla; atrofia múltipla; doença de Parkinson; tumores; acidente vascular cerebral (AVC), 

doenças discais; causas periféricas: como por exemplo: diabetes mellitus; alcoolismo; 

uremia, olineuropatia e cirúrgicas (pélvica, retroperitônio, prostatectomia radical); causas 

anatômicas ou estruturais: doença de Peyronie; fratura peniana; curvatura congênita do 

pênis; micropênis; hipospádias, epispádias. 

Hormonal: hipogonadismo; hiperprolactinemia, hiper e hipotireoidismo e doença de 

Cushing. 

Medicamentosa ou induzida por drogas: anti-hipertensivos (diuréticos e 

betabloqueadores), antidepressivos, antipsicóticos, antiandrogênicos, anti-histamínicos e 

drogas recreacionais (heroína, cocaína, metadona). 

Psicogênica: tipo generalizado: falta de excitabilidade e disfunções na intimidade 

sexual, tipo situacional: relacionamento com parceira, problemas relacionados ao desempenho 

sexual.  

O diagnóstico é eminentemente clínico, realizado após anamnese detalhada e exame 

clínico. Exames complementares podem auxiliar no diagnóstico, tais como, medida sérica da 

testosterona, glicemia de jejum e perfil lipídico, Ultrassonografia Doppler colorida com 



 

 19  
 

ereção fármaco induzida prévia, tumescência e rigidez peniana noturna (TRPN) utilizando 

Rigiscan (3, 13). Atualmente utiliza-se como ferramenta, tanto no diagnóstico como para 

avaliação em estudos clínicos o International Index for Erectile Function (IIEF), validada para 

o português como Índice Internacional de Função Erétil-5 (IIFE-5) (14). 

 

1.3 Tratamento da disfunção erétil  

 O tratamento, como na maioria das doenças, deve seguir o principio de ser 

individualizado e escalonado do menos invasivo e mais tolerado ao mais invasivo e menos 

tolerado. 

A orientação do homem e do casal sobre sua sexualidade é um ponto fundamental no 

tratamento da DE independente da etiologia. 

 A psicoterapia e tratamento com psicofármacos têm apresentado bons resultados, tendo 

em vista que, principalmente em pacientes jovens, a etiologia mais frequente é a psicogênica 

(15). 

Doenças concomitantes e principalmente as cardiovasculares que compartilham dos 

mesmos fatores de risco, devem ser devidamente tratadas. 

Estudo demonstrou que se os fatores de risco para doenças cardiovasculares forem 

manejados adequadamente, além do risco cardíaco diminuir a DE pode ser controlada (12). 

 

1.3.1 Tratamento de primeira linha 

Os inibidores da Fosfodiesterase 5 (PDE5) são considerados o tratamento de primeira 

linha para quase todas as etiologias. 



 

 20  
 

A escolha do inibidor da PDE5 deve ser adequada à expectativa do paciente. Estes 

devem ser adequadamente informados quanto às vantagens e possíveis desvantagens em seu 

uso. 

Como existem inibidores da PDE5 com meia vida variada comercializados no Brasil, é 

importante adaptar o tratamento aos hábitos sexuais do paciente, frequência de relações 

sexuais e a previsibilidade destas.  

O primeiro inibidor da PDE5, sildenafila (Viagra ®), introduzido no mercado em 1998, 

era utilizado de acordo com a necessidade (sob demanda) por suas características 

farmacológicas, principalmente a meia vida curta. Em 2008 a tadalafila (Cialis®) foi 

aprovada para uso diário continuo, facilitando pacientes que tenha atividade sexual mais 

frequente ou não previsível (3). 

São comercializados no Brasil, além dos já descritos, Vardenafila (Levitra®, Vivanza®) 

e Lodenafila (Helleva®). 

Outros inibidores da PDE5 se encontram registrados ou em fase de registro em outros 

países, como: Udenafila (Coreia e Rússia, pendente FDA), Avanafila (em avaliação FDA), 

Mirodenafila (Coreia), SLX-2101(fase II finalizado e em avaliação FDA) (16, 17).  

Os inibidores da PDE5 registrados no Brasil são medicamentos com perfil de segurança 

adequados com os eventos adversos e contra indicações, formais e relativas, bem 

estabelecidas. 

Por serem vasodilatadores os eventos adversos mais comuns se relacionam a esta ação, 

como cefaleia, vermelhidão, tontura e congestão nasal. As menos frequentes são 

anormalidades visuais, dor nas costas /mialgias, taquicardia, hipotensão, entre outros. 

Infartos do miocárdio não aumentaram após o uso de PDE5 em diversos estudos (18). 

Hipotensão ortostática é descrita com o uso concomitante a alfa-bloqueadores e finalmente, a 



 

 21  
 

contra indicação formal do uso com nitratos, por seus efeitos hipotensores imprevisíveis, 

podendo levar a baixa perfusão coronariana ao miocárdio.  

Doses menores de inibidores de PDE5 podem ser necessárias quando os pacientes 

estiverem recebendo cetoconazol, itraconazol, eritromicina, claritromicina e inibidores da 

protease do HIV (ritonavir, saquinavir). Doses maiores de inibidores de PDE5 podem vir a ser 

necessárias em pacientes que estão recebendo rifampicina, fenobarbital, fenitoína ou 

carbamazepina. A presença de insuficiência renal ou hepática pode levar à necessidade de 

ajuste da dose dos inibidores de PDE. 

Antes de se iniciar um tratamento de segunda ou terceira linha recomenda-se a 

reposição de testosterona, o que restabelece a eficácia em pacientes hipogonádicos não 

respondedores aos inibidores de PDE5, observadas todas as contra indicações formais e 

relativas desta reposição. 

 

1.3.2 Tratamentos de segunda linha 

Pacientes que não respondem adequadamente ao tratamento por via oral podem se 

beneficiar com o uso de medicamentos injetáveis no corpo cavernoso, como o alprostadil e a 

associação de medicamentos alprostadil + papaverina + fentolamina, menos indicada por seus 

maiores efeitos adversos, relacionados à papaverina, principalmente a fibrose. 

Ainda pode-se utilizar a prostaglandina E1 administrada por via intrauretral. 

 

1.3.3 Tratamento de terceira linha (prótese peniana) 



 

 22  
 

O implante cirúrgico de uma prótese peniana pode ser considerado para pacientes que 

não respondem a farmacoterapia ou que desejam uma solução permanente. As principais 

complicações do método são falhas mecânicas e infecção (3, 13, 19, 20).  

 

1.4 O desenvolvimento de um novo medicamento 

O desenvolvimento de um novo medicamento é um grande desafio. Desde a concepção 

da ideia até o registro de uma nova molécula o tempo despendido é extremamente longo e a 

taxa de sucesso é muito baixa (21, 22). 

 No Brasil, este desafio se torna ainda maior, graças a processos regulatórios morosos e 

cultura de pesquisa e desenvolvimento ainda embrionários. No entanto, este cenário vem se 

modificando rapidamente com a maior e efetiva participação das universidades e órgãos de 

fomentos governamentais importantes, como FINEP - Agência Brasileira da Inovação e 

BNDES – Banco Nacional do Desenvolvimento Econômico e Social (23).  

Uma invenção nem sempre se tornará uma inovação, este conceito é muito importante 

para que oriente grupos de pesquisa em nosso país.   

Se uma invenção não é apropriada comercialmente para gerar valor de uso não se 

tornará uma inovação.  

Para exemplificar, se a descoberta de nova entidade química (invenção) não seguir os 

preceitos acima não se tornará um medicamento inovador (24). 

O desenvolvimento sem o foco na apropriação comercial entra no processo de 

esquecimento e não melhora a qualidade de vida da população. No entanto uma invenção, 

mesmo não se transformando em uma inovação, pode gerar conhecimento para que outras 

possam ser verdadeiras inovações no futuro (25).  



 

 23  
 

As inovações são classicamente descritas como radical e incremental. As radicais 

costumam mudar paradigmas, enquanto que as incrementais estão relacionadas à melhoria da 

qualidade e aperfeiçoamento de produtos, processos e serviços. Apesar de sua complexidade 

menos aparente, as inovações incrementais são necessárias, tanto para melhorar a qualidade 

de vida da população, como para gerar ideias que poderão levar a uma inovação radical (23). 

Nas ciências da saúde, especialmente na medicina, estes conceitos são bastante úteis. 

Atualmente, toda inovação incremental é avaliada em relação ao seu custo-efetividade, 

comparada aos tratamentos tradicionais. A farmacoeconomia hoje é uma ciência e auxilia na 

decisão de utilização de um novo medicamento, tanto pelo médico, como, e principalmente, 

em termos de saúde pública (26, 27). 

Em relação ao tempo, custo e riscos inerentes processo inovador de um novo 

medicamente, sabe-se que;  

Se construirmos um gráfico onde em X plotamos o tempo de desenvolvimento (fases) e 

no Y o risco, observaremos que no início do processo o tempo e custo são menores, no 

entanto o risco é maior. Em contrapartida, em fases mais tardias do desenvolvimento – após a 

prova de conceito e estudos pré-clínicos – esta relação se inverte, o tempo e principalmente os 

custos aumentam exponencialmente.   

Quando se fala em medicamentos, sabe-se que de cada 10.000 moléculas prospectadas, 

10 a 20 terminam satisfatoriamente os estudos pré-clínicos, de 1 a 5 iniciam a fase de estudos 

clínicos e apenas uma será efetivamente aprovada pelos órgãos regulatórios (24).  

Ainda, acontecimentos recentes demonstram que, na fase IV o monitoramento da 

farmacovigilância e estudos de farmacoepidemiolgia podem retirar um medicamento do 

mercado por questões de risco sanitário, não detectados nas fases de estudos clínicos I, II e II. 



 

 24  
 

 Atualmente, tornou-se mais fácil demonstrar a eficácia de um medicamento do que 

garantir a sua segurança.  

 

1.4.1 Estudos clínicos: fase I; II, III e IV. 

Um novo medicamento, antes de iniciar a fase de estudos clínicos passa por estudos pré-

cínicos, in vitro e em animais.  

O objetivo destes estudos é determinar o possível mecanismo de ação de um novo 

medicamento, a eficácia e principalmente a segurança para que o mesmo possa ser testado em 

seres humanos. Nesta fase se determina a dose segura que se iniciará os estudos clínicos fase 

I.  

“Um ensaio clínico é um estudo sistemático de medicamentos e/ou especialidades 

medicinais em voluntários humanos que seguem estritamente as diretrizes do método 

científico. Seu objetivo é descobrir ou confirmar os efeitos e/ou identificar as reações 

adversas ao produto investigado e/ou estudar a farmacocinética dos ingredientes ativos, de 

forma a determinar sua eficácia e segurança” (28). 

Os ensaios clínicos são realizados, na maioria das vezes, para o desenvolvimento de 

novos medicamentos.  

São classicamente divididos em:  

 Fase I – onde se avalia a tolerabilidade, segurança e farmacocinética de um 

medicamento, geralmente são conduzidos em voluntários saudáveis. 

Fase II – conduzidos em pacientes portadores da patologia a qual o medicamento se 

destinará, geralmente o número de voluntários não é muito elevado e o objetivos destes 

estudos é avaliar a eficácia e principalmente a segurança do novo medicamento. 



 

 25  
 

Fase III - são estudos terapêuticos com um número maior de doentes, para determinação 

do risco-benefício do tratamento.  

 Fase IV – estudos também conhecidos como pós-marketing onde o objetivo é 

acompanhar o medicamento no mercado, visando principalmente o perfil de segurança do 

novo medicamento (29). 

 

Estudo Clínico Fase I  

Os estudos de Fase I, como já sumarizado acima, têm como objetivo testar a 

tolerabilidade, segurança e perfil farmacocinético de um novo medicamento. 

Como é o primeiro estudo onde seres humanos serão expostos, o delineamento deste 

deve levar sempre em consideração os dados de estudos pré-clínicos, principalmente 

relacionados às doses que apresentaram toxicidade nos modelos animais estudados. 

Existem várias maneiras de se calcular a dose inicial que será utilizada no estudo clínico 

fase I.  

O preconizado em vários guidelines e na literatura, inicialmente, calcula-se a dose 

máxima inicial (MRSD - maximum recommended starting dose -) – que é calculada após a 

determinação da dose equivalente human (HED - human equivalent dose), que por sua vez é 

calculada utilizando-se a NOAEL- no observed adverse effect levels – da espécie animal mais 

adequada, dentre as testadas durante a fase pré-clinica. Em seguida se aplica um fator de 

segurança, uma fração da HED, dependendo da classe do novo medicamento e do perfil de 

segurança esperado em seres humanos (30, 31, 32). 

Em seguida, o delineamento de um estudo fase I deve prever um escalonamento para 

atingir, se possível, a dose máxima tolerada, MTD - maximum tolerable dosage. Existem 



 

 26  
 

alguns modelos estatísticos para se aplicar ao escalonamento da dose, ou seja, as doses 

subsequentes à inicial, calculada conforme descrido acima. 

Habitualmente, se utiliza para estabelecer a próxima dose, em um estudo de 

escalonamento de dose, a sequência de Fibonacci. Esta foi formulada por Leonardo Pisano em 

1202 em um de seus problemas (problema dos coelhos) descritos no clássico Liber Abbaci, 

considerado um dos melhores tratados de aritmética e álgebra. 

Esta sequência, definida como, 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, 89, 144,... é obtida, a 

partir do terceiro número, pela soma dos dois antecessores. Simplificadamente pode ser obtida 

multiplicando-se o termo anterior por 1,618 (33, 34). 

Ainda, é importante estabelecer uma regra de escalonamento da dose que garanta 

segurança ao sujeito de pesquisa. Em estudos com medicamentos oncológicos esta regra é 

bastante criteriosa, detalhada e padronizada, pois estes estudos clínicos envolvem 

medicamentos com alto grau de toxicidade.  

 Esta regra leva em consideração a dose limite de toxicidade (DLT- dose-limiting 

toxicity), definida como a dose que apresenta acima de grau 3 de toxicidade, exceto 

neutropenia de grau 3, acompanhados ou não por febre ou infecção. 

 A escala em questão é a critério comum de toxicidade (CTC - common toxicity criteria) 

padronizada pelo Cancer Therapy Evaluation Program. Este critério estabelece variações de 

gravidade do evento adverso observado entre 0 e 4 e os categoriza por sistemas/órgãos. É 

utilizada na avaliação de eventos adversos durante o tratamento oncológico e em estudos 

clínicos envolvendo medicamentos desta classe, como já salientado (35). 

Resumidamente, a regra segue o seguinte esquema:  

- Inicialmente, organiza-se uma coorte de 3-6 voluntários por dose. Hipoteticamente 

utilizaremos uma coorte de 3 voluntários para exemplificar. 



 

 27  
 

Três voluntários são tratados com a dose inicial. Se, pelo menos, dois pacientes 

apresentam sinais de DLT, a dose prévia é definida como a dose máxima tolerada (MTD). Se 

nenhum dos 3 pacientes apresentam sinais e sintomas de DLT, a dose é aumentada para etapa 

seguinte em uma nova coorte de 3 voluntários, onde os critérios anteriores serão utilizados. Se 

nenhum dos três pacientes tratados apresentam sinais e sintomas de DLT, 3 pacientes 

adicionais são tratados com a dose atual. Se nenhum destes 3 voluntários adicionais 

apresentam sinais e sintomas de  DLT, a dose é aumentada para o próximo grupo de 3 

pacientes e o processo continua. A MTD é considerada como atingida quando pelo menos 2 

pacientes de um total de 6 pacientes são tratados (30). 

Apesar do perfil de segurança de outras classes de medicamentos, em geral , ser mais 

favorável, métodos de escalonamento de doses seguros devem sempre ser adotados, baseados 

nos resultados de estudos anteriosres não clínicos e perfil de segurança da classe 

farmacológica a que pertence o novo medicamento, quando possível (31, 36, 37). 

 

1.5 Estudos preliminares com o Carbonato de lodenafila  

Com o objetivo de pesquisar a possibilidade de um análogo da sildenafila com maior 

potência, seletividade e melhor perfil de segurança, foram sintetizados pelo Dipartimento di 

Chimica Farmacêutica da Università di Napoli “Federico II”, vinte moléculas (6 a-v), 

caracterizados pela presença de um grupo sulfonil ou de um substituinte n’n’etilendiamina na 

posição do grupo metil da piperazina. Estes análogos foram testados no departamento de 

farmacologia da Faculdade de Ciências Médicas – UNICAMP. 

Em plaquetas e músculo liso há elevada concentração de PDE5, é por este motivo que 

ensaios funcionais e bioquímicos em plaquetas e músculo liso têm sido bastante usados para o 

desenvolvimento de novos medicamentos visando seletividade na degradação do GMPc. 

Sendo assim, a metodologia adotada para testar estes análogos e selecionar os mais viáveis 



 

 28  
 

para o desenvolvimento de um novo medicamento inibidor da PDE5 foi utilizar, os seguintes 

ensaios: a atividade inibitória da PDE5 de plaquetas humanas, o efeito relaxante dos análogos 

do sildenafila em corpo cavernoso de coelho e o efeito relaxante dos análogos do sildenafila 

em anéis de aorta de coelho. Nos estudos com plaquetas para avaliar a atividade inibitória da 

PDE5 foi utilizado sangue de voluntários sadios. Nos estudos funcionais foram utilizados 

coelhos New Zealand machos (2-3 kg) procedentes do CEMIB-UNICAMP (38). 

Os compostos 6m, 6n e 6q demonstraram valores elevados de concentração efetiva 50% 

(IC50) para inibir a PDE5 plaquetária. Os 6a, 6b, 6d, 6g e 6p produziram inibição inferior a 

50%. A IC50 dos compostos 6c, 6e, 6f, 6h, 6l e 6o foram similares ao da sildenafila. 

Nos estudos funcionais, todos análogos da sildenafila, exceto o 6m, relaxaram 

preparações de corpo cavernoso de coelho de maneira dependente da concentração.  

O análogo 6f demonstrou o melhor perfil farmacológico no relaxamento, com potência 

similar ao sildenafila. 

Vários dos análogos testados demonstraram ser mais lipofílicos do que o sildenafila. 

Estes achados podem contribuir para o desenvolvimento de medicamentos para patologias que 

apresentem disfunção endotelial em sua etiopatogenia.  

Dando continuidade à definição da melhor molécula para atingir os objetivos propostos, 

avaliaram-se os efeitos dos análogos hidroxisetilildenafil, e os dímeros, carbonato, ureia e 

uretano. Estudou-se também o efeito máximo 50% (EC50), antilog da concentração de droga 

necessária para produzir 50% do efeito máximo (pEC50) em corpo cavernoso de rato e cães 

da raça beagle, a estabilidade e metabolização dos dímeros no plasma de rato, humano e cão. 

Avaliou-se também a farmacocinética dos dímeros em cão e o efeito da administração 

endovenosa sobre a pressão arterial e frequência cardíaca em cães da raça beagle.  



 

 29  
 

Com base nos resultados obtidos foi decidido que o dímero hidroetilsildenafil (em sua 

forma carbonato) foi o mais indicado para a próxima etapa da avaliação da toxicidade pré-

clínica (38, 39, 40). 

A patente do composto denominado CRIS035 foi depositada pelo laboratório Cristália 

Produtos Químicos Farmacêuticos Ltda. durante a fase experimental.  

1.5.1 Estudos pré-clínicos de toxicidade 

Foram realizados os ensaios de atividade mutagênica in vitro (Teste de Ames), estudos 

de toxicidade aguda em roedor (ratos) e estudos em um roedor (rato) e um não roedor (cão) 

com duração de 14 dias.  

No teste de Ames concluiu-se que:  

- O composto CRIS031 não demonstrou efeitos mutagênicos sobre as  linhagens TA 98, 

TA 100, TA 1535 e TA 1537 de Salmonella typhimurium testadas na presença ou na ausência 

da  fração microssomal metabolicamente ativa S9 de fígado de rato. 

Na toxidade aguda em ratos concluiu-se que: 

- Em condições experimentais a dose oral DL50 do teste é maior do que 2000mg/Kg. 

Não foram observados sinais de toxicidade nestas doses.  

Estudo de toxicidade de doses repetidas duas semanas em ratos com doses orais 

(Gavagem):  

- Não foram observados sinais de toxicidade em doses de tolerabilidade máxima (MTD) 

de 1000 mg/Kg. 

Estudo de toxidade em doses repetidas em 2 semanas por via oral (Gavagem) em cães 

(Beagle):  

- Não foram observados sinais de toxicidade em doses de 1000 mg/Kg 



 

 30  
 

Avaliação sobre a atividade do sistema nervosa central após dose oral única (gavagem) 

em roedores (ratos):  

- Nenhuma mortalidade ou morbidade foi observada após a administração de doses 

únicas (100, 550,775 e 1000 mg/Kg). 

- Nenhum distúrbio do comportamento foi observado, utilizando-se o functional 

observation battery (FOB).  

- Nenhuma alteração macroscópica foi observada - post-mortem (38, 39, 40).  

 

1.6 Objetivo  

 

O estudo foi conduzido para avaliar a segurança, tolerabilidade e farmacocinética do 

carbonato de lodenafil após administração em doses crescentes (1 a 100 mg), em dose única, 

em voluntários saudáveis. 

 

 

 

 

 

 

 

 

 



 

 31  
 

2. Capítulo I 

 

A phase I clinical trial of lodenafil carbonate, a new phosphodiesterase type 5 

(PDE5) inhibitor, in healthy male volunteers. 

Gustavo D. Mendesb, c*, Hilton Oliveira dos Santos Filhoa, Alberto dos Santos Pereirad, 

Fabiana D. Mendesa, Jaime O. Ilhad, Khalid M. Alkharfye &amp;amp; Gilberto De Nuccie,f 

 

aDepartment of Internal Medicine, State University of Campinas, Campinas/SP, Brazil 

bDepartment of Pharmacology, Faculty of Medical Sciences, State University of Campinas 

(UNICAMP), Campinas/SP, Brazil  

cFaculty of Odontology, University Camilo Castelo Branco (UNICASTELO), São Paulo, SP, 

Brazil 

dGaleno Research Unit, Latino Coelho St., 1301, Parque Taquaral, 13087-010, Campinas, SP, 

Brazil  

eDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 

Saudi Arabia 

fDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, São 

Paulo, Brazil. 

 

Running title: Lodenafil carbonate phase I study. 

*Corresponding author 

415 Jesu?no Marcondes Machado Ave.,  



 

 32  
 

13092-320, Campinas - SP, Brazil.  

Tel.: +55-193251-6928; fax: +55-19-3252-1516.  

E-mail: gugamendes@terra.com.br 

 

Abstract  

Lodenafil carbonate is a new phosphodiesterase type 5 (PDE5) inhibitor used in 

treatment of erectile dysfunction. Objective: The present study was conducted to evaluate the 

safety, tolerability, and pharmacokinetics of lodenafil carbonate after administering ascending 

(1 to 100 mg) single oral doses to healthy male volunteers (n=33). Methods: The study was an 

open-label, dose-escalation, phase I clinical trial involving the administration of single oral 

doses of lodenafil carbonate. Lodenafil carbonate was administered sequentially, escalating in 

single doses of 1 mg to 100 mg with a washout period of at least 1 week between each dose. 

The progression to the next dose was allowed after clinical and laboratory exams, Ambulatory 

Monitoring of Arterial Pressure (AMAP) without relevant clinical modifications and adverse 

events without clinical relevancy. Blood samples were collected at pre-dose, 0.25, 0.5, 0.75, 

1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24h post-dosing. 

Plasma samples for measurement of lodenafil carbonate and lodenafil were analyzed by liquid 

chromatography coupled to tandem mass spectrometry. Results: No serious adverse events 

were observed, and none of the subjects discontinued the study due to intolerance. The 

AMAP measurements, clinical and laboratory exams and ECG revealed no significant 

changes even at higher doses. Lodenafil carbonate was not detected in any samples, indicating 

that it acts as a pro-drug. The mean lodenafil pharmacokinetic parameters for tmax and t1/2 

were 1.6 (±0.4) hr and 3.3 (±1.1) hr, respectively. This study demonstrated that lodenafil 

carbonate was well tolerated and showed a good safety profile in healthy male volunteers. 



 

 33  
 

Key words: phosphodiesterase type 5 (PDE5) inhibitor, pharmacokinetics, safety 

 

 1. Introduction 

Lodenafil carbonate is a new phosphodiesterase type 5 (PDE5) inhibitor for treatment of 

erectile dysfunction [1]-[4], a common sexual problem for males over 40-50 years of age.  

Lodenafil relaxes isolated human and animal cavernous tissues through inhibition of cyclic 

guanosine monophosphate hydrolysis [1]. Lodenafil carbonate was approved by Brazilian 

Sanitary Surveillance Agency (ANVISA) in 2007 [5].  

The pharmacokinetic parameters for lodenafil carbonate and lodenafil following oral 

administration (10 mg) of lodenafil carbonate in male beagle dogs were (mean±S.D): 

lodenafil carbonate: 11±14 ng/mL, 23±21 ng*h/mL, 2.1±3.0 h, 1.67±1.53 h; lodenafil: 

1357±961 ng/mL, 9,091±5,526 ng*h/mL, 4.3±0.5 h, 4.3±0.5 h for Cmax, AUC, t1/2, tmax, 

respectively [1]. The above results indicate that lodenafil carbonate acts as a prodrug, 

delivering lodenafil in vivo as the active moiety, since very small amounts of lodefanil 

carbonate reached the systemic circulation. 

The tmax for PDE5 inhibitors is between 0.33 – 1.8 hours (sildenafil 1 h, tadalafil 1.8 h, 

vardenafil 0.75 h, udenafil 1 h and avanafil 0.33 h) and the half-life time for PDE5 inhibitors 

varies from 2.6 to 21.1 hours ( sildenafil 2.76 h, vardenafil 2.63 h, avanafil 5.36 h, udenafil 11 

h and tadalafil 21.1 h) [6]-[10]. After single oral administrations of lodenafil carbonate (160 

mg) in healthy male volunteers, lodenafil  is rapidly absorbed with peak of concentration (157 

ng/mL) occurring at ? 1.2 hours, half-life time of 2.4 hours and area under the curve (AUC) 

of 530 ng*h/mL [4]. 



 

 34  
 

The present study was conducted to evaluate the safety, tolerability, and 

pharmacokinetics of lodenafil carbonate after administering ascending (1 to 100 mg) single 

oral doses in normal healthy male volunteers.  

 

2. Materials and methods 

2.1. Clinical protocol 

The following inclusion criteria were used: Thirty-three healthy male volunteers, aged 

between 18 and 55 years old and within ? 19 and ? 28.75 of the ideal body weight were 

selected for the study [11]. The volunteers were selected for the study after having their health 

status previously assessed by a clinical evaluation and laboratory tests (biochemical and 

hematological parameters, and urinalysis). The volunteers were free from significant cardiac, 

hepatic, renal, pulmonary, neurological, gastrointestinal and hematological diseases, as 

assessed by clinical examination, ECG and the following laboratory tests: blood glucose, 

urea, creatinine, AST, ALT, alkaline phosphatase, ?GT, total bilirrubin and fractions, uric 

acid, total cholesterol, triglycerides, albumin and total protein, hemoglobin, hematocrit, total 

and differential white cell counts and routine urinalysis. All subjects were negative for HIV, 

HBV (except for serological scar) and HCV. The subjects were able to comprehend the full 

nature and purpose of the study, including possible risks and side effects and were willing to 

cooperate with the Investigator and comply with the requirements of the entire study. All 

subjects provided signed consent forms. 

The following exclusion criteria were used: laboratory values outside the accepted 

normal ranges, unless considered not clinically significant by the investigator; participation in 

an experimental study or had ingested an experimental drug three months prior to the 

initiation of the study; any significant clinical illness or surgery within eight weeks 



 

 35  
 

immediately prior to the initiation of the study or maintenance therapy with any drug; 

hospitalizing for any reason within eight weeks prior to the initiation of the study; history of 

drug, medication or alcohol abuse, or had ingested alcohol within 48 hours prior to the 

beginning of the confinement portion of the study; history of hepatic, renal, epileptic or 

hemopoietic disease; hypo or hypertension of any etiology (outside the range of 100-140 

mmHg for systolic and 60-90 mmHg for diastolic blood pressure), or heart rate not between 

50-90 bpm; myocardial infarction, angina pectoris and/or congestive heart failure; the subject 

had donated or lost blood within three months prior to the study or more than 1500mL within 

12 months preceding the study; any other condition as per investigator judgment; high 

caffeine intake (more than 5 cups of tea or coffee/day); subject who smoked; history or 

presence of gastrointestinal, liver or kidney disease or any other condition known to interfere 

with the absorption, distribution, metabolism or excretion of drugs.  

Concomitant medication was to be avoided where possible during the study. Any 

medication, including over-the-counter medication, was to be recorded. 

The male volunteers had the following clinical characteristics (mean ± SD [range]): age 

31.1± 5.7 yr. [23 – 40]; height 174 ± 6.1 cm [160.0 – 184.0]; body weight 71.2 ± 9.7 kg [54.5 

– 90.5]. All subjects provided written informed consent, and the Ethics Committee of the 

State University of Campinas approved the protocol. Any major changes required approval 

from the Committee. The study was conducted in accordance with Good Clinical Practices 

and provisions of the Declaration of Helsinki (1964) and all revisions.  

After screening and a washout period (of at least 2 weeks), the individuals who 

qualified were confined for 3 periods of approximately 40 hours. Each confinement was 

intervaled for 1 week. The study was conducted in an open, randomized, dose-escalation, 

three-period open-label experimental design, involving the administration of increasing single 



 

 36  
 

oral doses (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) of 

lodenafil carbonate (Table 1). A Fibonacci-like scheme was used for dose escalation (from 1-

10, and from 10-100 mg). The progression to the next dose was allowed by clinical and 

laboratory exams, Ambulatory Monitoring of Arterial Pressure (AMAP) without relevant 

clinical modifications, and adverse events without clinical relevancy. The adverse event 

evaluation was performed during confinement period and in a clinical visit 24h before the 

next confinement. The medical investigator classified the event intensity as mild, moderate, 

severe, and serious, and the causal relationship to the formulation as unrelated, unlikely, 

possible and probable.  

During each period, the volunteers were hospitalized between 4:00 and 7:00 p.m., 

having already eaten a normal evening meal. After overnight fasting, they received at 7:00 

a.m., a single dose of appropriate lodenafil carbonate (tablet) along with 240 ml of tap water. 

All volunteers were required to remain fasting until 2 hours after dose administration, when a 

xanthine-free standard breakfast was available. A xanthine-free standard lunch was provided 

five (lunch), eight (afternoon snack), twelve (lunch) and fifteen (supper) hours after dose. A 

standard meal (lunch) of rice, beans, vegetables, and fried chicken, plus a fruit as dessert was 

consumed. The breakfast, afternoon snack and supper included crackers, bread, jelly, cake and 

apple. No other food was permitted during the "in-house" period and liquid consumption was 

allowed ad libitum after lunch (with the exception of xanthine-containing drinks, including 

tea, coffee, and cola). No comedication was permitted during the study. 

Blood samples (5 mL) from a suitable antecubital vein were collected by an indwelling 

catheter into heparin containing tubes at pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 

3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24h post-dosing. 



 

 37  
 

The Ambulatory Monitoring of Arterial Pressure (AMAP) was measured for 24 hours 

after drug administration, with 15-minute intervals in the first two hours and then every hour 

until the end of the internment (24 hours after the administration of the lodenafil carbonate). 

Two ECGs were obtained one hour and twelve hours after the administration of the lodenafil 

carbonate.  

 

2.2 Formulations 

The following formulations were employed: lodenafil carbonate test formulation tablet 

in 1 mg (lot 318/04), 2 mg (lot 319/04), 3 mg (lot 320/04), 5 mg (lot 321/04), 8 mg (lot 

378/04), 10 mg (lot 379/04), 20 mg (lot 392/04), 30 mg (lot 391/04), 50 mg (lot 394/04), 80 

mg (lot 396/04) and 100 mg (lot 397/04) from Cristália Produtos Químicos e Farmacêuticos 

Ltda, Itapira, Brazil. 

 

2.3 Chemicals and reagents 

Lodenafil carbonate (lot number: SL24-024), lodenafil (lot number: not available), 

sildenafil (lot number: 20227/99) were provided by Cristália Produtos Químicos e 

Farmacêuticos Ltda, Itapira, Brazil. Acetonitrile, formic acid and methanol were purchased 

from J. T. Baker, USA. Diethyl ether and hexane were purchased from Mallinckrodt, USA. 

Blank human blood was collected from healthy, drug-free volunteers. Plasma was obtained by 

centrifugation of blood treated with sodium heparin. Pooled plasma was prepared and stored 

at approximately -20 ºC until needed. 

 

 



 

 38  
 

2.4 Calibration standards and quality controls 

Stock solutions of lodenafil carbonate, lodenafil and the internal standard (sildenafil) 

were prepared in acetonitrile/water (50/50, v/v) at concentrations of 1 mg/mL. Calibration 

curves of lodenafil carbonate and lodenafil were prepared by spiking blank plasma at 

concentrations of 0.5, 1.0, 5.0, 20.0, 50.0, 200, 1,000 and 2,000 ng/mL and each concentration 

was analyzed in duplicate. The quality control samples were prepared in blank plasma at 

concentrations of 3, 30, 180 and 1,800 ng/mL (QCA, QCB, QCC and QCD, respectively). 

The spiked plasma samples (standards and quality controls) were extracted in each analytical 

batch along with the unknown samples. 

 

2.5 Drug analysis 

The blood samples (5 mL) were centrifuged at 2500 g for 10 min at -4oC and the plasma 

decanted and stored at –200 C until assayed for lodenafil carbonate and lodenafil contents. 

Lodenafil carbonate, lodenafil, and the IS were extracted from plasma samples and quantified 

by liquid chromatography tandem mass spectrometry (LC-MS-MS) with positive electrospray 

ionization using multiple reaction monitoring (MRM). 

Briefly, 0.2 mL of each plasma sample was pipetted into a glass tube followed by 0.05 

mL of the internal standard solution (1,000 ng/mL of sildenafil (Cristália Produtos Químicos e 

Farmacêuticos Ltda, Itapira, Brazil.) and 4 mL of hexane/diethyl-ether (20/80; v/v) (HPLC 

grade, J. T. Baker, Phillipsburg, NJ, USA). The tubes were briefly vortex-mixed (40 s). The 

upper organic layers were removed and transferred into another sterile tube, and evaporated to 

dryness under N2 (at 40 ºC). The dry residues were dissolved with 0.2 mL of 

acetonitrile/water (50/50; v/v) and the solutions were transferred to glass microvials using 



 

 39  
 

automatic pipettes with disposable plastic tips. The vials were caped and placed into the 

autosampler racks. 

High performance liquid chromatography (HPLC) was performed on C18, 4 mm (100 x 

2.1 mm i.d. (Jones Chromatography, Genesis, USA) at a flow rate of 0.45 mL/min and 

pressure of the system was approximately 120 bar. The mobile phase was acetonitrile/water 

(90/100; v/v) + 0.1% formic acid (Analysis Grade, J. T. Baker, USA).  The column operated 

at room temperature. The temperature of the auto sampler operated at 10 ± 2 oC and the 

injection volume was 10 µL. 

Typical standard retention times were 1.1 ± 0.2 min for lodenafil carbonate, 0.8 ± 0.1 

min for lodenafil and 0.8 ± 0.1 min for the IS, and the total run-time was 2.4 min. The mass 

spectrometer (model API 4000, Sciex/Applied Biosystems, Foster City, CA, USA) equipped 

with a turbospray source using a crossflow counter electrode, was run in positive mode (ES+) 

with multiple reaction monitoring (MRM). The mass spectrometer was set as follows: 1035.2 

&gt; 487.1, 505.2 &gt; 487.0 and 475.1 &gt;283.2, for lodenafil carbonate, lodenafil and sildenafil, as 

the precursor ions and the respective product ions m/z. The limit of quantification in plasma 

was 0.5 ng/mL for both lodenafil carbonate and lodenafil. 

 

2.6 Assay performance 

A linear regression with a weighting index of 1/x^2 was performed on the peak area 

ratios of lodenafil carbonate and the internal standard versus the lodenafil carbonate 

concentrations of eight human plasma standards (in duplicate) to generate a calibration curve. 

A linear regression with a weighting index of 1/x^2 was performed on the peak area ratios of 

lodenafil and the internal standard versus the lodenafil concentrations of the eight human 

plasma standards (in duplicate) to generate a calibration curve. 



 

 40  
 

Precision and accuracy: Within- and between-run precision was determined as the 

relative standard deviation, RSD (%) = 100(SD/M), and the accuracy as the percentage 

relative error, RE (%) = (E-T)(100/T), where M is the mean, SD is the standard deviation of 

M, E is the experimentally determined concentration and T is the theoretical concentration. 

 

2.7 Pharmacokinetics  

Individual plasma level-time curves were constructed and pharmacokinetic parameters 

were obtained according to a non-compartmental approach. The first-order terminal 

elimination rate constant (ke) was estimated by linear regression from the points describing 

the elimination phase in a log-linear plot, and the half-life (t1/2) was derived from this rate 

constant (t1/2 = ln (2)/ke). The maximum plasma concentration (Cmax) and the time taken to 

achieve this concentration (tmax) were obtained directly from the curves. The areas under the 

lodenafil plasma concentration vs. time curves from time zero to the last detectable 

concentration (AUClast) were calculated by applying the linear trapezoid rule. Extrapolation of 

these areas to infinity (AUCinf) was done by adding the value Clast/ke to the calculated AUClast 

(where Clast = the last detectable concentration). Clearance (CL) was calculated by the 

formula dose/AUC0-inf. Volume of distribution (Vd) was calculated by the formula 

Dose/Ke(AUCinf). The software used included WinNonLin Professional Network Edition 

(Scientific Consulting, v. 3.0), Microsoft Excel (v. 7.0) and GraphPad Prism (v. 3.02). 

 

3. Results  

All biochemical parameters monitored presented no clinically relevant alterations 

during the phase I study. No significant changes were observed in the laboratory exams and in 

the ECGs intra-study.  Tolerance of both formulations (1 to 100 mg) was good and no 



 

 41  
 

significant adverse event were observed or reported. One volunteer had an adverse event 

(dysuria not related to therapy and classified as not serious) after the discharge of the third 

confinement period during the phase I study. Two volunteers related spontaneous erections 

after administration of lodenafil carbonate (30 and 50 mg): one during the clinical evaluation 

for discharge of the study and one during the final clinical evaluation in the first period of 

confinement. 

Laboratory tests after administration of lodenafil carbonate are shown in Table 4. Blood 

pressure and heart rate were assessed for 24 hours after treatment with lodenafil carbonate 

(Figure 2; Table 5).  

The mean lodenafil plasma concentrations vs. time profiles after testing single oral 

doses of lodenafil carbonate in males are shown in Figure 1. Calculated mean 

pharmacokinetic parameters of lodenafil are given in Table 3.  

The method was linear for lodenafil carbonate and lodenafil concentrations from 0.5 to 

2000 ng/mL. No significant matrix effect was observed. The limit of quantification (LOQ), 

defined as the lowest concentration at which both the precision and accuracy were&amp;lt;20%, was 

0.5 ng/mL for lodenafil carbonate and lodenafil. The within- and between-run precision and 

accuracy for the quality controls are summarized in Table 2. 

 

4. Discussion 

High-performance liquid chromatography (HPLC) coupled with tandem mass 

spectrometry (LC-MS-MS) in animal and human plasma has been used for lodenafil and/or 

lodenafil carbonate quantification [1][4]. However, no full validation method has been 

previously published for lodenafil and lodenafil carbonate quantification. Our method 

employed sildenafil as internal standard instead of theophylline, having a shorter retention 



 

 42  
 

time of 1.1 min for lodenafil carbonate and 0.8 min for lodenafil. The limit of quantification 

(0.5 ng/ml) was adequate for pharmacokinetic evaluation of lodenafil carbonate and lodenafil.  

The results obtained following oral administration of lodenafil carbonate in healthy 

male volunteers show that lodenafil carbonate acts as a prodrug when given orally, since no 

quantifiable lodefanil carbonate concentration has been detected in the systemic circulation. 

Similar results were observed in male beagles following oral administration of lodenafil 

carbonate [1].  

The adverse event of dysuria was evaluated as not serious since the volunteer 

spontaneously recovered and only reported in the medical final evaluation.  

After the oral administration of the lodenafil carbonate 80 mg tablets to the volunteers, 

the tmax (1.6h) and t1/2 (3.3h) were similar to the reported in the literature (tmax: 1.2 -1.5h; 

t1/2: 2.4 – 3h) [2]. The Cmax (17.62 ng/mL) and AUC (42.80 hr*ng/mL) values were 

different to those reported in the literature (Cmax 158 ng/mL; AUC 528 hr*ng/mL) for a 

lodenafil carbonate tablet (dose 160 mg; two tablets of 80 mg) formulation [2].  

As shown in Table 3, the pk parameters calculated for 1 mg are not reliable due to low 

plasma lodenafil after a dose of 1 mg. The major differences for t1/2, Cl and Vd over the dose 

range can be explained by the low number (n=3 to 1 mg; n=6 to 2mg and n=9 between 3 mg 

and 100 mg) of volunteer per dose and by the variability inter-subject. 

The mean lodenafil pharmacokinetic parameters for tmax (1.6±0.4 hr) was similar to the 

PDE5 (sildenafil 1 h, tadalafil 1.8 h, vardenafil 0.75 h, udenafil 1 h, and avanafil 0.33 h). The 

mean lodenafil pharmacokinetic parameters for t1/2 (3.3h) were similar to the sildenafil and 

vardenafil  (sildenafil 2.76 h, vardenafil 2.63 h, avanafil 5.36 h, udenafil 11 h and tadalafil 

21.1 h) [6]-[10]. 



 

 43  
 

No serious adverse events were observed, and none of the subjects discontinued the 

study because of lack of tolerance. As shown in Tables 4 and 5, the AMAP measurements and 

clinical tests revealed no significant alteration even at a higher dose. The lodenafil carbonate 

presented good tolerance and safety for healthy male volunteers in phase I study. The 

recommended dose of 80 mg was used in following trials and it is the commercial formulation 

dose marketed in Brazil. 

 

Acknowledgements: The Phase I trial was sponsored by Cristália Produtos Químicos e 

Farmacêuticos Ltda, Itapira, Brazil. AcademicEnglishSolutions.com revised the English. 

References:  

[1] Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De 

Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 

(PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J 

Pharmacol. 2008;591(1-3):189-95.  

[2] Silva AC, Toffoletto O, Lucio LA, Santos PF, Afiune JB, Massud Filho 

J, Tufik S. [Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, 

with and without alcohol consumption]. Arq Bras Cardiol. 2010;94(2):150-6. 

[3] Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF, 

Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile 

dysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553-7.  

[4] Glina S, Fonseca GN, Bertero EB, Damião R, Rocha LC, Jardim CR, 

Cairoli CE, Teloken C, Torres LO, Faria GE, da Silva MB, Pagani E. Efficacy and 

tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III 

clinical trial. J Sex Med. 2010;7(5):1928-36.  



 

 44  
 

[5] Diário Oficial da União – DOU, 

http://www.in.gov.br/imprensa/visualiza/index.jsp?jornal=1010&amp;amp;pagina=22&amp;amp;data=22/

10/2007. 

[6] Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on 

sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin 

Pharmacol. 2010 Jan;69(1):23-6. 

[7] Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, 

Sabo JP, Dellamonica P. Effect of tipranavir/ritonavir combination on the 

pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011 

Jul;51(7):1071-8.  

[8] Berry B, Altman P, Rowe J, Vaisman J. Comparison of 

Pharmacokinetics of Vardenafil Administered Using an Ultrasonic Nebulizer for 

Inhalation vs. a Single 10-mg Oral Tablet. J Sex Med. 2009 Jul 28.  

[9] Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, Paick JS, Ahn 

TY, Min KS, Park K, Park JK. Eur Urol. Efficacy and safety of once-daily dosing of 

udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, 

double-blind, placebo-controlled trial. 2011 Aug;60(2):380-7. 

[10] Jung J, Choi S, Cho SH, Ghim JL, Hwang A, Kim U, Kim BS, Koguchi 

A, Miyoshi S, Okabe H, Bae KS, Lim HS. Tolerability and pharmacokinetics of 

avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-

blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male 

volunteers. Clin Ther. 2010 Jun;32(6):1178-87. 



 

 45  
 

[11] Report of the Dietary Guidelines Advisory Committee on the Dietary 

Guidelines for Americans, 2000, 

http://www.health.gov/dietaryguidelines/dgac/pdf/dgac_ful.pdf 

[12] Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset 

phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin 

Investig Drugs. 2010;19(11):1427-37. 

[13] De Nucci G. Estudo clínico fase I do carbonato de lodenafila em 

voluntários sadios do sexo masculino. Int Braz J Urol. 2007; 33 (Suppl 2): 148. 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 46  
 

Table 1: Treatment scheme with lodenafil in 1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 

30 mg, 50 mg, 80 mg and 100 mg in healthy male volunteers. 

Volunteer 1 mg 2 mg 3 mg 5 mg 8 mg 10 mg 20 mg 30 mg 50 mg 80 mg 100 mg 
I x x x         
II x x x         
III x x x         
IV  x x x        
V  x x x        
VI  x x x        
VII   x x x       
VIII   x x x       
IX   x x x       
X    x x x      
XI    x x x      
XII    x x x      
XIII     x x x     
XIV     x x x     
XV     x x x     
XVI      x x x    
XVII      x x x    
XVIII      x x x    
XIX       x x x   
XX       x x x   
XXI       x x x   
XXII        x x x  
XXIII        x x x  
XXIV        x x x  
XXV         x x x 
XXVI         x x x 
XXVII         x x x 
XXVIII          x x 
XXIX          x x 
XXX          x x 
XXXI           x 
XXXII           x 
XXXIII           x 

 

 

 

 



 

 47  
 

Table 2: Accuracy and precision data for lodenafil carbonate and lodenafil from the pre-study 
validation in human plasma. 
 

Lodenafil carbonate 

Nominal 
concentration 

(in ng/mL) 

Intra-batch mean 
(in ng/mL) 

Intra-
batch 

precision 
(CV %) 

Intra-
batch 

accuracy 
(%) 

Inter-
batch 

mean (in 
ng/mL) 

Inter-
batch 

precision 
(CV%) 

Inter-
batch 

accuracy 
(%) 

0.5 0.55 12.55% 109.29% 
0.52 15.38% 103.42% 0.5 0.47 14.16% 93.70% 

0.5 0.53 17.01% 105.89% 
3 3.1 3.61% 102.42% 

3.2 8.70% 105.17% 3 3.1 4.01% 104.50% 
3 3.3 14.98% 109.72% 

30 32.8 4.25% 109.25% 
33.3 9.32% 110.89% 30 33.9 10.23% 113.08% 

30 33.1 12.38% 110.33% 
180 187.3 2.33% 104.03% 

189.5 6.16% 105.30% 180 191.4 3.11% 106.32% 
180 190.0 10.30% 105.56% 

1800 1923 6.06% 106.81% 
1894 5.91% 105.23% 1800 1935 5.39% 107.50% 

1800 1825 5.03% 101.39% 
Lodenafil 

Nominal 
concentration 

(in ng/mL) 

Intra-batch mean 
(in ng/mL) 

Intra-
batch 

precision 
(CV %) 

Intra-
batch 

accuracy 
(%) 

Inter-
batch 

mean (in 
ng/mL) 

Inter-
batch 

precision 
(CV%) 

Inter-
batch 

accuracy 
(%) 

0.5 0.54 19.67% 107.13% 
0.51 16.39% 101.02% 0.5 0.48 19.02% 96.37% 

0.5 0.50 7.95% 100.33% 
3 2.8 11.33% 92.29% 

2.7 9.66% 90.26% 3 2.7 7.36% 89.75% 
3 2.7 10.79% 88.52% 

30 28.7 5.25% 95.63% 
27.6 8.42% 91.97% 30 27.8 10.50% 92.75% 

30 25.8 5.18% 86.06% 
180 163.5 5.48% 90.83% 

157.7 8.69% 87.59% 180 157.9 6.61% 87.71% 
180 151.6 12.27% 84.24% 

1800 1604 3.60% 89.10% 
1623 5.32% 90.14% 1800 1685 4.41% 93.61% 

1800 1579 5.88% 87.71% 
 

Legends: CV = coefficient of variation; 
 

 



 

 48  
 

Table 3: Mean pharmacokinetic parameters obtained from volunteers after administration of 
lodenafil carbonate formulation (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 
80 mg and 100 mg) in 33 healthy volunteers. 
 

Dose (mg) 1.00 2.00 3.00 5.00 

Variable Mean SD Mean SD Mean SD Mean SD 

AUC Extrap (%) 65.65 36.92 32.61 23.63 31.39 18.59 30.15 23.04 

AUCinf (hr*ng/mL) 15.99 13.19 7.02 3.65 12.82 5.26 12.13 6.02 

AUClast (hr*ng/mL) 2.07 1.98 3.67 2.37 8.11 3.84 6.45 5.89 

Cmax (ng/mL) 1.76 1.61 2.87 1.67 2.77 0.42 3.71 2.36 

tmax (hr) 0.75 0.00 1.17 0.49 2.06 2.46 2.22 2.06 

Ke (1/hr) 0.17* 0.20 0.47 0.25 0.30 0.29 0.33 0.20 

t1/2 (hr) 14.62* 17.54 2.37 2.38 4.02 2.25 3.33 2.61 

Vd (L) 1009.00* 750.00 925.00 463.00 1266.00 472.00 1951.00 1299.00 

Cl (L/hr) 95.00* 78.00 355.00 189.00 283.00 147.00 497.00 228.00 

Dose (mg) 8.00 10.00 20.00 30.00 

Variable Mean SD Mean SD Mean SD Mean SD 

AUC Extrap (%) 31.08 23.41 24.27 24.18 6.75 4.08 14.82 18.71 

AUCinf (hr*ng/mL) 22.62 15.73 29.69 24.85 55.53 39.71 86.69 85.97 

AUClast (hr*ng/mL) 17.54 16.34 24.99 24.45 46.18 39.87 82.40 86.41 

Cmax (ng/mL) 8.08 6.92 10.92 12.20 19.21 13.74 24.39 19.37 

tmax (hr) 2.11 1.29 1.38 0.50 1.86 1.99 1.44 0.92 

Ke (1/hr) 0.35 0.20 0.41 0.35 0.42 0.30 0.25 0.13 

t1/2 (hr) 2.97 2.23 2.66 1.92 2.59 1.75 3.78 2.61 

Vd (L) 2348.00 1908.00 2435.00 2435.00 1477.00 789.00 6037.00 7740.00 

Cl (L/hr) 613.00 553.00 796.00 821.00 490.00 257.00 1007.00 1175.00 

Dose (mg) 50.00 80.00 100.00 Mean 

Variable Mean SD Mean SD Mean SD Mean SD 

AUC Extrap (%) 5.90 4.83 21.07 29.71 5.23 3.53 - - 

AUCinf (hr*ng/mL) 65.91 51.90 49.16 39.69 89.72 73.32 - - 

AUClast (hr*ng/mL) 63.37 51.36 42.80 41.95 86.66 73.25 - - 

Cmax (ng/mL) 24.09 15.39 17.62 15.40 37.27 29.02 - - 

tmax (hr) 1.67 1.04 1.86 1.08 1.42 1.02 1.6 0.4 

Ke (1/hr) 0.32 0.12 0.25 0.16 0.33 0.16 0.3 0.1 

t1/2 (hr) 2.59 1.25 5.93 9.12 2.56 1.24 3.3 1.1 

Vd (L) 4137.00 2902.00 22971.00 28532.00 5581.00 3189.00 4913 6590.5 

Cl (L/hr) 1361.00 1189.00 3274.00 2955.00 1784.00 1120.00 1046 914.7 
 

Legends: Ke = elimination rate constant; t1/2 = half-life; Cmax = maximum plasma concentration; tmax 
= time to the maximum plasma concentration, AUClast - area under curve from time zero to the last 

detectable concentration AUCinf = extrapolation of area to infinity, AUC Extrap = % extrapolation of 
area to infinity; CL = clearance; VD = volume of distribution; Clast = last detectable concentration, 

tlast = time of last detectable concentration, * = excluded of descriptive statistic. 
 



 

 49  
 

Table 4: Laboratory tests in healthy male volunteers after administration of lodenafil 
carbonate. 

 

Type Unit Normal range 

Pre-study Pos-study 

Mean SD Min Max Mean SD Min Max 

H
em

at
ol

og
ic

al
 

Hemoglobin g% 13.5 - 17.5 15.4 0.8 14.1 17.2 14.6 0.8 12.9 16.8 
Hematocrit % 39 - 50 44.7 1.9 42.2 49.4 42.9 2.1 40.1 47.7 

Red Blood Count 106/mm3  4.3 - 5.7 5.2 0.6 4.7 8.0 4.8 0.2 4.5 5.2 
VCM Micra3  81 - 95 84.4 17.1 5.2 93.6 89.0 2.4 85.3 93.3 

HbCM pg 26 - 34 29.6 3.4 14.9 33.4 30.3 1.3 27.4 32.9 
White Blood Count 103/mm3 3500 - 10500 6.4 1.3 3.7 8.4 6.9 1.7 4.2 10.6 
Band Neutrophils % ? 5 1.7 1.0 1.0 5.0 1.7 0.7 1.0 3.0 

Segmented  % 48 - 76 55.0 8.6 36.1 66.7 54.6 8.7 32.1 65.8 
Lymphocytes % 25 - 30 31.9 8.6 18.4 50.3 31.8 7.9 21.9 51.5 

Monocytes % 1 - 9 7.7 1.7 4.7 10.3 7.8 2.2 4.8 12.0 
Basophils % 0 - 1 0.6 0.4 0.0 1.8 0.5 0.3 0.0 1.0 

Eosinophils % 1 - 5  3.8 2.8 0.6 10.7 4.0 2.5 1.0 9.9 
Platelet Count - 150 – 400 238.5 50.0 153.0 363.0 247.3 44.4 162.0 328.0 

B
io

ch
em

ic
al

 

Total Cholesterol  mg/dL  ? 239 167.3 30.9 112.0 239.0 165.5 42.0 22.0 248.0 
Triglycerids mg/dL ? 150 102.4 44.5 45.0 191.0 99.6 54.1 24.0 303.0 

Total Proteins g/dL 6 - 8 7.8 0.3 7.3 8.4 7.7 0.3 7.2 8.3 
Albumin g/dL 3.5 - 5.5 4.7 0.2 4.4 5.0 4.6 0.2 4.2 5.1 
Uric Acid mg/dL 2.5 – 7.0 5.5 1.5 3.1 9.0 5.4 1.3 3.0 8.8 

Total Bilirubins mg/dL 0 - 1.1 0.8 0.5 0.4 2.6 0.6 0.4 0.0 1.4 
Alkaline Phosphatase U/L 27 - 100 76.2 18.9 49.0 115.0 67.6 24.5 0.8 116.0 

gT U/L   24.1 11.9 8.0 63.0 23.8 11.2 5.2 47.0 
SGOT  (AST) U/L ? 43 21.9 5.5 15.0 42.0 20.2 4.1 12.0 34.0 
SGPT  (ALT) U/L ? 43 23.2 11.0 13.0 64.0 23.1 9.7 10.0 53.0 

Urea mg/dL 10 - 50 26.6 5.4 14.4 36.7 29.1 5.5 17.2 38.0 
Creatinine mg/dL 0.4 - 1.3 1.1 0.8 0.8 4.7 1.1 0.9 0.7 4.5 

Fasting Blood Glucose mg/dL 60 - 100 87.2 8.1 74.0 108.0 87.9 6.9 74.0 101.0 

U
ri

n
e 

Specific Gravity - 1.015 - 1.028 1019.3 5.8 1008.0 1029.0 1019.6 6.1 1006.0 1032.0 
pH - 5.5 - 6.5 6.2 0.6 5.5 7.0 6.2 0.4 5.5 6.5 

WBC /mL ? 10000 7124.2 16901.9 300.0 97000.0 3277.0 1924.3 1000.0 9400.0 
RBC /mL ? 5000 4150.0 4784.6 300.0 19430.0 2900.0 3924.6 100.0 22900.0 

 

 

 

 

 

 

 

 



 

 50  
 

Table 5: Mean sitting systolic and diastolic blood pressures and mean heart rates after 

lodenafil carbonate administration. 

Time 

Mean diastolic blood 

pressures 

Mean systolic blood 

pressures Mean heart rate 

Mean SD Min Max Mean SD Min Max Mean SD Min Max 

0 71 7 56 89 113 8 91 132 63 7 41 86 

1 70 7 54 93 113 8 86 134 59 7 42 77 

2 72 8 52 96 114 8 88 134 61 8 43 85 

3 69 9 45 99 115 8 88 145 65 10 45 100 

4 68 9 41 93 115 10 95 138 66 10 43 107 

5 71 10 44 97 118 9 89 143 72 11 48 107 

6 65 9 40 89 113 10 77 135 67 8 49 85 

7 66 10 40 96 112 9 85 133 68 10 46 99 

8 67 9 40 93 112 10 90 135 66 10 46 92 

9 65 11 43 86 112 16 90 140 65 12 46 97 

10 66 9 43 88 112 11 84 143 68 10 48 92 

11 68 11 44 90 114 10 86 138 65 10 48 92 

12 74 10 50 98 117 11 94 149 70 14 47 111 

13 70 11 44 95 117 10 93 146 69 11 47 104 

14 69 10 44 89 116 10 82 143 70 10 49 102 

15 64 10 46 94 112 11 91 142 66 10 46 99 

16 65 8 46 84 113 10 83 144 67 11 45 115 

17 62 9 44 80 110 10 84 135 64 10 44 89 

18 63 10 41 89 110 11 86 136 62 11 42 98 

19 63 8 43 81 108 8 87 127 62 13 42 138 

20 65 8 45 88 109 10 88 133 62 10 42 87 

21 62 10 43 91 105 11 83 142 60 10 46 105 

22 62 10 40 84 105 12 79 132 59 9 41 82 

23 63 11 42 91 106 11 74 127 61 11 39 98 

24 73 8 54 91 116 7 98 132 70 9 49 91 

 



 

 51  
 

Figure 1: The mean lodenafil plasma concentrations vs. time profiles after a single oral dose (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 

10 mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) tablet formulation of lodenafil carbonate in male volunteers. 

  

  

  

  

  

 

  Dose - 100 mg

0 2 4 6 8 10 12 14 16 18 20 22 24

0

10

20

30

40

Time ( h)

M
e

an
 C

o
n

c
en

tr
a

ti
o

n
(n

g
/m

L
)



 

 52  
 

Figure 2: Mean sitting systolic and diastolic blood pressures and sitting heart rates after 

lodenafil carbonate administration. 

Effect on blood pressure of lodenafil carbonate

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

40

50

60

70

80

90

100

110

120

130

140

Diastolic Blood Pressure Systolic Blood Pressure

Time (h)

m
m

H
g

 

Mean heart rate

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

40

50

60

70

80

90

100

Time (h)

M
e
an

 h
e
ar

t 
ra

te
/m

in

 

 



 

 53  
 

3. Discussão 

 

A cromatografia líquida de alto desempenho (HPLC), acoplado com espectrometria de 

massa (LC-MS-MS) tem sido utilizada para quantificação de carbonato de lodenafila e ou 

lodenafila no plasma humano e de animais. No entanto, nenhum método de validação 

completo foi publicado anteriormente para quantificação de lodenafila e carbonato de 

lodenafila. O nosso método emprega sildenafila como padrão interno em vez de teofilina, 

tendo um tempo de retenção mais curto de 1,1 min. para o carbonato de lodenafila e 0,8 min. 

para lodenafila. O limite de quantificação (0,5 ng / ml) foi adequado para avaliação de 

farmacocinética de carbonato lodenafila e lodenafila. 

Os resultados obtidos após a administração oral de carbonato de lodenafila em 

voluntários saudáveis do sexo masculino mostraram que o carbonato de lodenafila atua como 

um pró-droga quando administrado por via oral, uma vez que nenhuma concentração 

quantificável de carbonato de lodefanila foi detectada na circulação sistêmica. Resultados 

semelhantes foram observados em beagles machos após a administração oral de carbonato 

lodenafila. 

O evento adverso disúria não foi considerado como relacionado à terapia uma vez que 

ocorreu 74 horas após a administração da droga (20 mg) e a média do tempo de meia-vida 

para lodenafila é de 3,3 horas. Foi avaliado como não grave, pois ocorreu recuperação 

espontânea e o voluntário apenas o relatou na avaliação médica final. 

Após a administração oral de comprimidos de carbonato de lodenafila 80 mg, para os 

voluntários, o tmax (1.6h) e t1/2 (3.3h) foram similares ao descrito na literatura  (tmax: 1.2 -

1.5h; t1/2: 2.4 – 3h). Os valores de Cmax (17.62 ng/mL) e a AUC (42.80 hr*ng/mL) foram 

diferentes daqueles relatados na literatura (Cmax 158 ng/mL; AUC 528 hr*ng/mL) para a 



 

 54  
 

formulação de comprimidos de carbonato de lodenafila (dose 160 mg; dois comprimidos de 

80 mg). 

Os parâmetros farmacocinéticos calculados para 1 mg não são confiáveis devido à baixa 

concentração de lodenafila no plasma após uma dose de 1 mg. A maior diferença para  t1/2, 

Cl e Vd ,ao longo do intervalo de dose, pode ser explicada pelo baixo número de voluntários 

por dose  (n=3 para 1 mg; n=6 para 2mg e n=9 entre 3 mg and 100 mg)  e pela variabilidade 

inter-sujeitos. 

As médias dos parâmetros farmacocinéticos de lodenafila para Tmax (1,6 ± 0,4 hr) foi 

semelhante aos PDE5 (sildenafila 1 h, tadalafila1, 8 h, vardenafila 0,75 h, udenafila 1 h, e 

avanafila 0,33 h). A média dos parâmetros farmacocinéticos de lodenafila de t1 / 2 (3.3 h) foi 

similar à sildenafila e vardenafila (sildenafila 2,76 h, vardenafila 2,63 h, avanafila 5,36 h, 

udenafila 11 h e tadalafila 21,1 h). 

 

 

 

 

 

 

 

 

 

 

 

 



 

 55  
 

4. Conclusão 

 

Não foi observado evento adverso grave e nenhum dos voluntários descontinuou o 

estudo por falta tolerabilidade. 

O Carbonato de Lodenafila apresenta boa tolerabilidade e segurança no estudo fase I 

com voluntários saudáveis. 

A dose recomendada de 80 mg foi usada em estudos clínicos posteriores a este e é a 

formulação comercializada no Brasil. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 56  
 

5. Referências bibliográficas 

 
1. Morgentaler A. Male impotence. Lancet. 1999;354(9191):1713-8. 

2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and 
predictors. JAMA. 1999;281(6):537-44. 

3. Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G,et al.  European 
Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol. 
2012;62(2):324-32. 

4. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot 
Res. 2003;15(1):63-71. 

5. Moreira ED Jr, Lbo CF, Diament A, Nicolosi A, Glasser DB.  Incidence of erectile 
dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. 
Urology. 2003;61(2):431-6. 

6. Abdo C, Oliveira Júnior  WM, Scanavino MT, Martins Gi. Disfunção erétil: resultados do 
estudo da vida sexual do brasileiro. Rev Assoc Med Bras. 1992;52(6):424-9. 

7. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ. 2004;170(9):1429-37. 

8. Qiu Y, Kraft P, Lombardi E, Clancy J. Rabbit corpus cavernosum smooth muscle shows a 
different phosphodiesterase profile than human corpus cavernosum. J Urol. 2000;164(3 Pt 
1):882-6. 

9.  Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot 
Res. 2004;16 Suppl. 1:S4-7.  

10. Aversa A. Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes. 
2010;1(1):3-7.  

11. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: 
endothelial dysfunction is the common denominator. Heart. 2003;89(3):251-3. 

12. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the 
US. Am J Med. 2007;120(2):151. 

13. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. 
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur 
Urol. 2010;57(5):804-14. 

14. Santos Pechorro P, Martins Calvinho A, Monteiro Pereira  N, Xavier Vieira R.  Validação 
de uma versão portuguesa do Índice Internacional de Função Eréctil-5 (IIEF-5).  Rev Int 
Androl. 2011;9(1):3-9.  



 

 57  
 

15. Simopoulos EF, Trinidad AC. Male erectile dysfunction: integrating psychopharmacology 
and psychotherapy. Gen Hosp Psychiatry. 2013;35(1):33-8. 

16. Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 
inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 
2010;19(11):1427-37.  

17. Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging 
drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2010;15(3):467-80. 

18. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of 
phosphodiesterase type 5 inhibitors. J Sex Med. 2009;6(3):658-74.  

19. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, et al. British Society for 
Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med. 
2008;5(8):1841-65. 

20. Eardley I. Oral therapy for erectile dysfunction. Arch Esp Urol. 2010;63(8):703-14. 

21. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug 
development costs. J Health Econ. 2003;22(2):151-85. 

22. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for 
new drugs by therapeutic category. A study of the US pharmaceutical industry.  
Pharmacoeconomics. 1995;7(2):152-69. 

23. Tironi LF, Cruz BDO. Inovação Incremental ou radical: há motivos para diferenciar? Uma 
abordagem com dados da PINTEC. 2008; texto para discussão nº 1360. 

24. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug 
Discov. 2004;3(8):711-5. 

25. Tidd J, Trewhella MJ. Organizational and technological antecedents for knowledge 
acquisition and learning. R&amp;amp;D Management. 1997; 27(4),359-75. 

26. Natércia F. Parcerias e inovação impulsionam setor farmacêutico. Inovação Unicamp. 
2005; 1(3): 32-7. 

27. Santos M. Estratégias tecnológicas em transformação: um estudo da indústria 
farmacêutica brasileira. Dissertação (Mestrado em Engenharia de Produção). Universidade 
Federal de São Carlos, São Carlos. 2010. 190 p.  

28. Organização Pan-Americana da Saúde, Organização Mundial da Saúde, Rede Pan-
Americana para Harmonização da Regulamentação Farmacêutica. Boas Práticas Clínicas: 
Documento das Américas. Brasília: Opas/OMS; 2005. 

29. Quental C, Salles Filho S. Ensaios clínicos: capacitação nacional para avaliação de 
medicamentos e vacinas. Rev  Bras Epidemiol. 2006;9(4): 408-24. 



 

 58  
 

30. Woolley PV, Schein PS. Clinical pharmacology and phase I trial design. Methods in 
Cancer Research. 1979;17: 177-98. 

31. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for 
industry - Estimating the maximum safe starting dose in initial clinical trials for therapeutics 
in adult healthy volunteers. US Department of Health and Human Services, 2005. 

  

32. Agência Nacional de Vigilância Sanitária. Guia para a condução de estudos não clínicos 
de segurança necessários ao desenvolvimento de medicamentos.  Disponível em: 
http://portal.anvisa.gov.br/wps/wcm/connect/e0f1d9004e6248049d5fddd762e8a5ec/Guia+de+
Estudos+N%C3%A3o+Cl%C3%ADnicos+-+vers%C3%A3o+2.pdf?MOD=AJPERES. 
Acesso em: 15.01.2013.  

33. Schneiderman MA. Mouse to man: statistical problems in bringing a drug to clinical trial. 
In Proceedings of the fifth Berkeley symposium on mathematical statistics and probability. 
1967; 4: 855-66. 

34. Pereira LDC, Ferreira M V. Sequência de Fibonacci: história, propriedades e relações com 
a razão áurea. Disc. Scientia. 2008,9(1): 67-81. 

35. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: 
development of a comprehensive grading system for the adverse effects of cancer treatment. 
Semin Radiat Oncol. 2003;13(3):176-81. 

36. Mahmood I, Green MD, Fisher JE. Selection of the first-time dose in humans: comparison 
of different approaches based on interspecies scaling of clearance. J Clin Pharmacol. 
2003;43(7):692-7. 

37. Vijayaraghavan R, Kumar GR. Impact of phase zero trials (micro-dosing) in clinical trial 
research. Int J Appl Biol Pharm Tech. 2010;2:486-90. 

38. Flores Toque HA, Priviero FB, Teixeira CE, Perissutti E, Fiorino F, Severino B, et al. 
Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile 
dysfunction. J Med Chem. 2008;51(9):2807-15.  

39. De Nucci G, Lorenzetti R, Okuyama C E, Baracat JS, Donato JL, Antunes E, et al. 
Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor 
lodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology.2008; 
7(Suppl. 1), 13. 

40. Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G. 
Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor 
lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 2008;591(1-
3):189-95.  

  



adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado

adriana.yamaguchi
Texto digitado
59



 

 60  
 

ANEXO II 

 

De: Jörg Feistle [mailto:joerg.feistle@dustri.de]  

Enviada em: segunda-feira, 10 de junho de 2013 03:20 

Para: 'Hilton Oliviera Santos' 

Cc: 'Gilberto De Nucci' 

Assunto: AW: A phase I clinical trial of lodenafil carbonate, a new phosphodiesterase type 5 (PDE5) 

inhibitor, in healthy male volunteers. - (Manuscript-ID 201624 - 3) 

 Dear Doctor Santos Filho, 

 Thank you for your email. Dustri-Verlag grants permission to include the text of the article 

 H. Oliveira dos Santos Filho, A. dos Santos Pereira, F. D. Mendes, T. Babadópulos, J. O. Ilha, K.M. 
Alkharfy, G.D. Mendes and G. De Nucci: A phase I clinical trial of lodenafil carbonate, a new 
phosphodiesterase type 5 (PDE5) inhibitor, in healthy male volunteers 

 of our Int. Journal of Clinical Pharmacology and Therapeutics, Vol. 50, no. 12/2012, pp. 896-906, in 
your thesis, as requested in your letter. 

 We request to give full credit to the author and publisher, either as a foot note, or as a reference 
within the text or both. 

 Sincerely yours, 

  

Joerg Feistle  
Dustri-Verlag Dr. Karl Feistle GmbH &amp;amp; Co. KG  
Bajuwarenring 4  
82041 Oberhaching, Germany  
P.O. Box 1351  
82032 Deisenhofen, Germany  
Phone +49-89-613861-30  
Fax +49-89-613861-80  
Email Joerg.Feistle@dustri.com  

http://www.dustri.com, http://www.clinnephrol.com, http://www.clinpharmacol.com  

Court of Registry: Local Court of Munich, Germany, HRA 81557, CEO: Joerg Feistle, Frank Feistle, Gerhard Feistle  

 

 

 

 

 

 

adriana.yamaguchi
Texto digitado



 

 61  
 

ANEXO III 

 

Estudo publicado:  

Int J Clin Pharmacol Ther. 2012 Dec;50(12):896-906.  

A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) 
inhibitor, in healthy male volunteers. 

Mendes GD, dos Santos Filho HO, dos Santos Pereira A, Mendes FD, Ilha JO, Alkharfy 
KM, De Nucci G. 

SourceDepartment of Pharmcology, State University of Campinas, Campinas, Brazil. 
gugamendes@terra.com.br 

Abstract 

Lodenafil carbonate is a new phosphodiesterase Type 5 (PDE5) inhibitor used in treatment of 
erectile dysfunction. Objective: The present study was conducted to evaluate the safety, 
tolerability, and pharmacokinetics of lodenafil carbonate after administering ascending (1 - 
100 mg) single oral doses to healthy male volunteers (n = 33). Methods: The study was an 
open label, dose-escalation, Phase I clinical trial involving the administration of single oral 
doses of lodenafil carbonate. Lodenafil carbonate was administered sequentially, escalating in 
single doses of 1 mg - 100 mg with a washout period of at least 1 week between each dose. 
The progression to the next dose was allowed after clinical and laboratory exams, Ambulatory 
Monitoring of Arterial Pressure (AMAP) without relevant clinical modifications and adverse 
events without clinical relevancy. Blood samples were collected at pre-dose, 0.25, 0.5, 0.75, 
1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24 h post-dosing. 
Plasma samples for measurement of lodenafil carbonate and lodenafil were analyzed by liquid 
chromatography coupled to tandem mass spectrometry. Results: No serious adverse events 
were observed, and none of the subjects discontinued the study due to intolerance. The 
AMAP measurements, clinical and laboratory exams and ECG revealed no significant 
changes even at higher doses. Lodenafil carbonate was not detected in any samples, indicating 
that it acts as a prodrug. The mean lodenafil pharmacokinetic parameters for tmax and t1/2 
were 1.6 ( ± 0.4) h and 3.3 ( ± 1.1) h, respectively. This study demonstrated that lodenafil 
carbonate was well tolerated and showed a good safety profile in healthy male volunteers. 

 

PMID:23073140[PubMed - in process] 

 

adriana.yamaguchi
Texto digitado



Original
©2012 Dustri-Verlag Dr. K. Feistle 

ISSN 0946-1965 

DOI 10.5414/CP201624
e-pub: October 17, 2012

Received
July 18, 2011;
accepted
May 28, 2012

Correspondence to 
Gustavo D. Mendes, MD 
415 Jesu?no Marcondes 
Machado Ave., 
13092-320, Campinas 
– SP, Brazil 
gugamendes@ 
terra.com.br

Key words
phosphodiesterase Type 
5 (PDE5) inhibitor- phar-
macokinetics – erectile 
disfunction – iodenofil 
carbonate

A Phase I clinical trial of lodenafil carbonate, 
a new phosphodiesterase Type 5 (PDE5) 
inhibitor, in healthy male volunteers
Gustavo D. Mendes1,2, Hilton Oliveira dos Santos Filho3, Alberto dos Santos Pereira4, 
Fabiana D. Mendes3, Jaime O. Ilha4, Khalid M. Alkharfy5 and Gilberto De Nucci6

1Department of Pharmacology, Faculty of Medical Sciences, State University of 
Campinas (UNICAMP), Campinas/SP, 2Faculty of Odontology, 3Department of 
Internal Medicine, University Camilo Castelo Branco (UNICASTELO), São Paulo, SP, 
4Galeno Research Unit, Campinas, SP, Brazil, 5Department of Clinical Pharmacy, 
College of Pharmacy, King Saud University, Riyadh, Saudi Arabia, and 
6Department of Pharmacology, Institute of Biomedical Sciences, University of Sao 
Paulo, São Paulo, Brazil

Abstract. Lodenafil carbonate is a new 
phosphodiesterase Type 5 (PDE5) inhibitor 
used in treatment of erectile dysfunction. 
Objective: The present study was conduct-
ed to evaluate the safety, tolerability, and 
pharmacokinetics of lodenafil carbonate 
after administering ascending (1 – 100 mg) 
single oral doses to healthy male volunteers 
(n = 33). Methods: The study was an open-
label, dose-escalation, Phase I clinical trial 
involving the administration of single oral 
doses of lodenafil carbonate. Lodenafil car-
bonate was administered sequentially, esca-
lating in single doses of 1 mg – 100 mg with 
a washout period of at least 1 week between 
each dose. The progression to the next dose 
was allowed after clinical and laboratory 
exams, Ambulatory Monitoring of Arterial 
Pressure (AMAP) without relevant clinical 
modifications and adverse events without 
clinical relevancy. Blood samples were col-
lected at pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 
1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 
12, 14, 16, 20 and 24 h post-dosing. Plasma 
samples for measurement of lodenafil car-
bonate and lodenafil were analyzed by liq-
uid chromatography coupled to tandem mass 
spectrometry. Results: No serious adverse 
events were observed, and none of the sub-
jects discontinued the study due to intoler-
ance. The AMAP measurements, clinical 
and laboratory exams and ECG revealed no 
significant changes even at higher doses. 
Lodenafil carbonate was not detected in any 
samples, indicating that it acts as a prodrug. 
The mean lodenafil pharmacokinetic param-
eters for tmax and t1/2 were 1.6 ( ± 0.4) h and 
3.3 ( ± 1.1) h, respectively. This study dem-
onstrated that lodenafil carbonate was well 
tolerated and showed a good safety profile in 
healthy male volunteers.

Introduction

Lodenafil carbonate is a new phosphodi-
esterase Type 5 (PDE5) inhibitor for treat-
ment of erectile dysfunction [1, 2, 3, 4], a 
common sexual problem for males over 
40 – 50 years of age. Lodenafil relaxes iso-
lated human and animal cavernous tissues 
through inhibition of cyclic guanosine mo-
nophosphate hydrolysis [1]. Lodenafil car-
bonate was approved by Brazilian Sanitary 
Surveillance Agency (ANVISA) in 2007 [5].

The pharmacokinetic parameters for lode-
nafil carbonate and lodenafil following oral 
administration (10 mg) of lodenafil carbon-
ate in male beagle dogs were (mean ± S.D): 
lodenafil carbonate: 11 ± 14 ng/ml, 23 ± 21 
ng×h/ml, 2.1 ± 3.0 h, 1.67 ± 1.53 h; lodenafil: 
1,357 ± 961 ng/ml, 9,091 ± 5,526 ng×h/ml, 
4.3 ± 0.5 h, 4.3 ± 0.5 h for Cmax, AUC, t1/2, 
tmax, respectively [1]. The above results indi-
cate that lodenafil carbonate acts as a prodrug, 
delivering lodenafil in vivo as the active moi-
ety, since very small amounts of lodefanil car-
bonate reached the systemic circulation.

The tmax for PDE5 inhibitors is between 
0.33 – 1.8 h (sildenafil 1 h, tadalafil 1.8 h, 
vardenafil 0.75 h, udenafil 1 h and avanafil 
0.33 h) and the half-life time for PDE5 in-
hibitors varies from 2.6 to 21.1 h (sildenafil 
2.76 h, vardenafil 2.63 h, avanafil 5.36 h, 
udenafil 11 h and tadalafil 21.1 h) [6, 7, 8, 
9, 10]. After single oral administrations of 
lodenafil carbonate (160 mg) in healthy male 
volunteers, lodenafil is rapidly absorbed with 

International Journal of Clinical Pharmacology and Therapeutics, Vol. 50 – No. 12/2012 (896-906) 



Lodenafil carbonate Phase I study 897

peak of concentration (157 ng/ml) occurring 
at 1.2 h, half-life time of 2.4 h and area under 
the curve (AUC) of 530 ng×h/ml [4].

The present study was conducted to eval-
uate the safety, tolerability, and pharmaco-
kinetics of lodenafil carbonate after admin-
istering ascending (1 – 100 mg) single oral 
doses in normal healthy male volunteers.

Materials and methods

Clinical protocol

The following inclusion criteria were 
used: 33 healthy male volunteers, aged be-
tween 18 and 55 years old and within ? 19 
and ? 28.75 of the ideal body weight were 
selected for the study [11]. The volunteers 

were selected for the study after having their 
health status previously assessed by a clinical 
evaluation and laboratory tests (biochemical 
and hematological parameters, and urinaly-
sis). The volunteers were free from signifi-
cant cardiac, hepatic, renal, pulmonary, neu-
rological, gastrointestinal and hematological 
diseases, as assessed by clinical examina-
tion, ECG and the following laboratory tests: 
blood glucose, urea, creatinine, AST, ALT, 
alkaline phosphatase, ?GT, total bilirrubin 
and fractions, uric acid, total cholesterol, 
triglycerides, albumin and total protein, he-
moglobin, hematocrit, total and differential 
white cell counts and routine urinalysis. All 
subjects were negative for HIV, HBV (except 
for serological scar) and HCV. The subjects 
were able to comprehend the full nature and 
purpose of the study, including possible risks 

Table 1. Treatment scheme with lodenafil in 1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 
mg, 80 mg and 100 mg in healthy male volunteers.

Volunteer 1 mg 2 mg 3 mg 5 mg 8 mg 10 mg 20 mg 30 mg 50 mg 80 mg 100 mg
I x x x
II x x x
III x x x
IV x x x
V x x x
VI x x x
VII x x x
VIII x x x
IX x x x
X x x x
XI x x x
XII x x x
XIII x x x
XIV x x x
XV x x x
XVI x x x
XVII x x x
XVIII x x x
XIX x x x
XX x x x
XXI x x x
XXII x x x
XXIII x x x
XXIV x x x
XXV x x x
XXVI x x x
XXVII x x x
XXVIII x x
XXIX x x
XXX x x
XXXI x
XXXII x
XXXIII x



Mendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 898

and side effects and were willing to cooper-
ate with the investigator and comply with the 
requirements of the entire study. All subjects 
provided signed consent forms.

The following exclusion criteria were 
used: laboratory values outside the accepted 
normal ranges, unless considered not clini-
cally significant by the investigator; partici-
pation in an experimental study or ingestion 
of an experimental drug 3 months prior to the 
initiation of the study; any significant clini-
cal illness or surgery within 8 weeks imme-
diately prior to the initiation of the study or 

maintenance therapy with any drug; hospi-
talization for any reason within 8 weeks prior 
to the initiation of the study; history of drug, 
medication or alcohol abuse, or had ingested 
alcohol within 48 hours prior to the begin-
ning of the confinement portion of the study; 
history of hepatic, renal, epileptic or hemo-
poietic disease; hypo- or hypertension of 
any etiology (outside the range of 100 – 140 
mmHg for systolic and 60 – 90 mmHg for 
diastolic blood pressure), or heart rate not 
between 50 and 90 bpm; myocardial infarc-
tion, angina pectoris and/or congestive heart 

Table 2. Accuracy and precision data for lodenafil carbonate and lodenafil from the pre-study validation 
in human plasma.

Lodenafil carbonate
Nominal 

concentration 
(in ng/ml)

Intra-batch 
mean 

(in ng/ml)

Intra-batch 
precision 
(CV %)

Intra-batch 
accuracy 

(%)

Inter-batch 
mean 

(in ng/ml)

Inter-batch 
precision 
(CV%)

Inter-batch 
accuracy 

(%)
0.5 0.55 12.55% 109.29% 0.52 15.38% 103.42%
0.5 0.47 14.16% 93.70%
0.5 0.53 17.01% 105.89%
3 3.1 3.61% 102.42% 3.2 8.70% 105.17%
3 3.1 4.01% 104.50%
3 3.3 14.98% 109.72%

30 32.8 4.25% 109.25% 33.3 9.32% 110.89%
30 33.9 10.23% 113.08%
30 33.1 12.38% 110.33%
180 187.3 2.33% 104.03% 189.5 6.16% 105.30%
180 191.4 3.11% 106.32%
180 190.0 10.30% 105.56%

1,800 1,923 6.06% 106.81% 1894 5.91% 105.23%
1,800 1,935 5.39% 107.50%
1,800 1,825 5.03% 101.39%

Lodenafil
Nominal 

concentration 
(in ng/ml)

Intra-batch 
mean 

(in ng/ml)

Intra-batch 
precision 
(CV %)

Intra-batch 
accuracy 

(%)

Inter-batch 
mean 

(in ng/ml)

Inter-batch 
precision 
(CV%)

Inter-batch 
accuracy 

(%)
0.5 0.54 19.67% 107.13% 0.51 16.39% 101.02%
0.5 0.48 19.02% 96.37%
0.5 0.50 7.95% 100.33%
3 2.8 11.33% 92.29% 2.7 9.66% 90.26%
3 2.7 7.36% 89.75%
3 2.7 10.79% 88.52%
30 28.7 5.25% 95.63% 27.6 8.42% 91.97%
30 27.8 10.50% 92.75%
30 25.8 5.18% 86.06%
180 163.5 5.48% 90.83% 157.7 8.69% 87.59%
180 157.9 6.61% 87.71%
180 151.6 12.27% 84.24%

1,800 1,604 3.60% 89.10% 1623 5.32% 90.14%
1,800 1,685 4.41% 93.61%
1,800 1,579 5.88% 87.71%

CV = coefficient of variation.



Lodenafil carbonate Phase I study 899

failure; the subject had donated or lost blood 
within 3 months prior to the study or more 
than 1,500 ml within 12 months preceding 
the study; any other condition as per inves-
tigator judgment; high caffeine intake (more 
than 5 cups of tea or coffee/day); subject who 
smoked; history or presence of gastrointesti-
nal, liver or kidney disease or any other con-
dition known to interfere with the absorp-
tion, distribution, metabolism or excretion of 
drugs.

Concomitant medication was to be 
avoided where possible during the study. 
Any medication, including over-the-counter 
medication, was to be recorded.

The male volunteers had the following 
clinical characteristics (mean ± SD (range)): 
age 31.1 ± 5.7 y (23 – 40); height 174 ± 6.1 
cm (160.0 – 184.0); body weight 71.2 ± 9.7 
kg (54.5 – 90.5). All subjects provided written 
informed consent, and the Ethics Committee 
of the State University of Campinas approved 
the protocol. Any major changes required ap-
proval from the Committee. The study was 
conducted in accordance with Good Clinical 
Practices and provisions of the Declaration of 
Helsinki (1964) and all revisions.

After screening and a washout period 
(of at least 2 weeks), the individuals who 
qualified were confined for 3 periods of ~ 40 

Table 3. Mean pharmacokinetic parameters obtained from volunteers after administration of lodenafil carbonate formulation (1 mg, 
2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg and 100 mg) in 33 healthy volunteers.

Dose (mg) 1.00 2.00 3.00 5.00
Variable Mean SD Mean SD Mean SD Mean SD
AUC Extrap (%) 65.65 36.92 32.61 23.63 31.39 18.59 30.15 23.04
AUC? (h×ng/ml) 15.99 13.19 7.02 3.65 12.82 5.26 12.13 6.02
AUClast (h×ng/ml) 2.07 1.98 3.67 2.37 8.11 3.84 6.45 5.89
Cmax (ng/ml) 1.76 1.61 2.87 1.67 2.77 0.42 3.71 2.36
tmax (h) 0.75 0.00 1.17 0.49 2.06 2.46 2.22 2.06
Ke (1/h) 0.17* 0.20 0.47 0.25 0.30 0.29 0.33 0.20
t1/2 (h) 14.62* 17.54 2.37 2.38 4.02 2.25 3.33 2.61
Vd (l) 1,009.00* 750.00 925.00 463.00 1,266.00 472.00 1,951.00 1,299.00
Cl (l/h) 95.00* 78.00 355.00 189.00 283.00 147.00 497.00 228.00

Dose (mg) 8.00 10.00 20.00 30.00
Variable Mean SD Mean SD Mean SD Mean SD
AUC Extrap (%) 31.08 23.41 24.27 24.18 6.75 4.08 14.82 18.71
AUC? (h×ng/ml) 22.62 15.73 29.69 24.85 55.53 39.71 86.69 85.97
AUClast (h×ng/ml) 17.54 16.34 24.99 24.45 46.18 39.87 82.40 86.41
Cmax (ng/ml) 8.08 6.92 10.92 12.20 19.21 13.74 24.39 19.37
tmax (h) 2.11 1.29 1.38 0.50 1.86 1.99 1.44 0.92
Ke (1/h) 0.35 0.20 0.41 0.35 0.42 0.30 0.25 0.13
t1/2 (h) 2.97 2.23 2.66 1.92 2.59 1.75 3.78 2.61
Vd (l) 2,348.00 1,908.00 2,435.00 2,435.00 1,477.00 789.00 6,037.00 7,740.00
Cl (l/h) 613.00 553.00 796.00 821.00 490.00 257.00 1,007.00 1,175.00

Dose (mg) 50.00 80.00 100.00 Mean
Variable Mean SD Mean SD Mean SD Mean SD
AUC Extrap (%) 5.90 4.83 21.07 29.71 5.23 3.53 – –
AUC? (h×ng/ml) 65.91 51.90 49.16 39.69 89.72 73.32 – –
AUClast (h×ng/ml) 63.37 51.36 42.80 41.95 86.66 73.25 – –
Cmax (ng/ml) 24.09 15.39 17.62 15.40 37.27 29.02 – –
tmax (h) 1.67 1.04 1.86 1.08 1.42 1.02 1.6 0.4
Ke (1/h) 0.32 0.12 0.25 0.16 0.33 0.16 0.3 0.1
t1/2 (h) 2.59 1.25 5.93 9.12 2.56 1.24 3.3 1.1
Vd (l) 4,137.00 2,902.00 22,971.00 28,532.00 5,581.00 3,189.00 4,913 6,590.5
Cl (l/h) 1,361.00 1,189.00 3,274.00 2,955.00 1,784.00 1,120.00 1,046 914.7

Ke = elimination rate constant; t1/2 = half-life; Cmax = maximum plasma concentration; tmax = time to the maximum plasma concentra-
tion, AUClast = area under curve from time zero to the last detectable concentration AUC? = extrapolation of area to infinity, AUC Ex-
trap = % extrapolation of area to infinity; CL = clearance; VD = volume of distribution; Clast = last detectable concentration, tlast = time 
of last detectable concentration, *excluded of descriptive statistic.



Mendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 900

Figure 1. The mean lodenafil plasma concentrations vs. time profiles after a single oral dose (1 mg, 2 mg, 
3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) tablet formulation of lodenafil carbonate 
in male volunteers.



Lodenafil carbonate Phase I study 901

hours. Each confinement was intervaled for 1 
week. The study was conducted in an open, 
randomized, dose-escalation, three-period 
open-label experimental design, involving 
the administration of increasing single oral 
doses (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 
mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) 
of lodenafil carbonate (Table 1). A Fibonac-
ci-like scheme was used for dose escalation 
(from 1 to 10, and from 10 to 100 mg). The 
progression to the next dose was allowed by 
clinical and laboratory exams, Ambulatory 
Monitoring of Arterial Pressure (AMAP) 
without relevant clinical modifications, and 
adverse events without clinical relevancy. 
The adverse event evaluation was performed 
during confinement period and in a clinical 
visit 24 hours before the next confinement. 
The medical investigator classified the event 
intensity as mild, moderate, severe, and se-
rious, and the causal relationship to the for-

mulation as unrelated, unlikely, possible and 
probable.

During each period, the volunteers were 
hospitalized between 4:00 p.m. and 7:00 
p.m., having already eaten a normal evening 
meal. After overnight fasting, they received 
at 7:00 a.m., a single dose of appropriate 
lodenafil carbonate (tablet) along with 240 
ml of tap water. All volunteers were required 
to remain fasting until 2 hours after dose ad-
ministration, when a xanthine-free standard 
breakfast was available. A xanthine-free 
standard lunch was provided 5 (lunch), 8 (af-
ternoon snack), 12 (lunch) and 15 (supper) 
hours after dose. A standard meal (lunch) of 
rice, beans, vegetables, and fried chicken, 
plus a fruit as dessert was consumed. The 
breakfast, afternoon snack and supper in-
cluded crackers, bread, jelly, cake and apple. 
No other food was permitted during the 
“in-house” period and liquid consumption 

Table 4. Laboratory tests in healthy male volunteers before and after administration of lodenafil carbonate.

Type Unit Normal range Pre-study Post-study
Mean SD Min Max Mean SD Min Max

H
em

at
ol

og
ic

al

Hemoglobin g% 13.5 – 17.5 15.4 0.8 14.1 17.2 14.6 0.8 12.9 16.8
Hematocrit % 39 – 50 44.7 1.9 42.2 49.4 42.9 2.1 40.1 47.7
Red blood count 106/mm3 4.3 – 5.7 5.2 0.6 4.7 8.0 4.8 0.2 4.5 5.2
VCM Micra3 81 – 95 84.4 17.1 5.2 93.6 89.0 2.4 85.3 93.3
HbCM Pg 26 – 34 29.6 3.4 14.9 33.4 30.3 1.3 27.4 32.9
White blood count 103/mm3 3,500 – 10,500 6.4 1.3 3.7 8.4 6.9 1.7 4.2 10.6
Band neutrophils % ? 5 1.7 1.0 1.0 5.0 1.7 0.7 1.0 3.0
Segmented % 48 – 76 55.0 8.6 36.1 66.7 54.6 8.7 32.1 65.8
Lymphocytes % 25 – 30 31.9 8.6 18.4 50.3 31.8 7.9 21.9 51.5
Monocytes % 1 – 9 7.7 1.7 4.7 10.3 7.8 2.2 4.8 12.0
Basophils % 0 – 1 0.6 0.4 0.0 1.8 0.5 0.3 0.0 1.0
Eosinophils % 1 – 5 3.8 2.8 0.6 10.7 4.0 2.5 1.0 9.9
Platelet count – 150 – 400 238.5 50.0 153.0 363.0 247.3 44.4 162.0 328.0

B
io

ch
em

ic
al

Total cholesterol mg/dl ? 239 167.3 30.9 112.0 239.0 165.5 42.0 22.0 248.0
Triglycerids mg/dl ? 150 102.4 44.5 45.0 191.0 99.6 54.1 24.0 303.0
Total proteins g/dl 6 –  8 7.8 0.3 7.3 8.4 7.7 0.3 7.2 8.3
Albumin g/dl 3.5 –  5.5 4.7 0.2 4.4 5.0 4.6 0.2 4.2 5.1
Uric acid mg/dl 2.5 – 7.0 5.5 1.5 3.1 9.0 5.4 1.3 3.0 8.8
Total bilirubins mg/dl 0 –  1.1 0.8 0.5 0.4 2.6 0.6 0.4 0.0 1.4
Alkaline phosphatase U/L 27 –  100 76.2 18.9 49.0 115.0 67.6 24.5 0.8 116.0
gT U/L  24.1 11.9 8.0 63.0 23.8 11.2 5.2 47.0
SGOT (AST) U/L ? 43 21.9 5.5 15.0 42.0 20.2 4.1 12.0 34.0
SGPT (ALT) U/L ? 43 23.2 11.0 13.0 64.0 23.1 9.7 10.0 53.0
Urea mg/dl 10 – 50 26.6 5.4 14.4 36.7 29.1 5.5 17.2 38.0
Creatinine mg/dl 0.4 – 1.3 1.1 0.8 0.8 4.7 1.1 0.9 0.7 4.5
Fasting blood glucose mg/dl 60 – 100 87.2 8.1 74.0 108.0 87.9 6.9 74.0 101.0

U
rin

e

Specific bravity – 1.015 – 1.028 1019.3 5.8 1,008.0 1,029.0 1,019.6 6.1 1,006.0 1,032.0
pH – 5.5 – 6.5 6.2 0.6 5.5 7.0 6.2 0.4 5.5 6.5
WBC /ml ? 10,000 7,124.2 16,901.9 300.0 97,000.0 3,277.0 1,924.3 1,000.0 9,400.0
RBC /ml ? 5,000 4,150.0 4,784.6 300.0 19,430.0 2,900.0 3,924.6 100.0 22,900.0



Mendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 902

was allowed ad libitum after lunch (with the 
exception of xanthine-containing drinks, in-
cluding tea, coffee, and cola). No comedica-
tion was permitted during the study.

Blood samples (5 ml) from a suitable an-
tecubital vein were collected by an indwell-
ing catheter into heparin containing tubes at 
pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 
2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 
and 24 h post-dosing.

The Ambulatory Monitoring of Arterial 
Pressure (AMAP) was measured for 24 hours 
after drug administration, with 15-min inter-
vals in the first 2 hours and then every hour 
until the end of the internment (24 hours 
after the administration of the lodenafil car-
bonate). Two ECGs were obtained 1 hour 
and 12 hour after the administration of the 
lodenafil carbonate.

Formulations

The following formulations were em-
ployed: lodenafil carbonate test formulation 
tablet in 1 mg (lot 318/04), 2 mg (lot 319/04), 
3 mg (lot 320/04), 5 mg (lot 321/04), 8 mg 
(lot 378/04), 10 mg (lot 379/04), 20 mg (lot 
392/04), 30 mg (lot 391/04), 50 mg (lot 
394/04), 80 mg (lot 396/04) and 100 mg (lot 
397/04) from Cristália Produtos Químicos e 
Farmacêuticos Ltda, Itapira, Brazil.

Chemicals and reagents

Lodenafil carbonate (lot number: SL24-
024), lodenafil (lot number: not available), 
sildenafil (lot number: 20227/99) were pro-
vided by Cristália Produtos Químicos e 
Farmacêuticos Ltda, Itapira, Brazil. Aceto-
nitrile, formic acid and methanol were pur-
chased from J. T. Baker, USA. Diethyl ether 
and hexane were purchased from Mallinck-
rodt, USA. Blank human blood was collect-
ed from healthy, drug-free volunteers. Plas-
ma was obtained by centrifugation of blood 
treated with sodium heparin. Pooled plasma 
was prepared and stored at approximately 
–20 °C until needed.

Calibration standards and quality 
controls

Stock solutions of lodenafil carbonate, 
lodenafil and the internal standard (silde-
nafil) were prepared in acetonitrile/water 
(50/50, v/v) at concentrations of 1 mg/ml. 
Calibration curves of lodenafil carbonate 
and lodenafil were prepared by spiking blank 
plasma at concentrations of 0.5, 1.0, 5.0, 
20.0, 50.0, 200, 1,000 and 2,000 ng/ml and 
each concentration was analyzed in dupli-
cate. The quality control samples were pre-
pared in blank plasma at concentrations of 3, 
30, 180 and 1,800 ng/ml (QCA, QCB, QCC 
and QCD, respectively). The spiked plasma 
samples (standards and quality controls) 
were extracted in each analytical batch along 
with the unknown samples.

Drug analysis

The blood samples (5 ml) were centri-
fuged at 2,500 g for 10 min at 4 °C and the 
plasma decanted and stored at –20 °C until 
assayed for lodenafil carbonate and lodenafil 
contents. Lodenafil carbonate, lodenafil, and 
the IS were extracted from plasma samples 
and quantified by liquid chromatography 
tandem mass spectrometry (LC-MS-MS) 
with positive electrospray ionization using 
multiple reaction monitoring (MRM).

Briefly, 0.2 ml of each plasma sample 
was pipetted into a glass tube followed by 
0.05 ml of the internal standard solution 
(1,000 ng/ml of sildenafil (Cristália Produtos 
Químicos e Farmacêuticos Ltda, Itapira, Bra-
zil.) and 4 ml of hexane/diethyl-ether (20/80; 
v/v) (HPLC grade, J. T. Baker, Phillipsburg, 
NJ, USA). The tubes were briefly vortex-
mixed (40 s). The upper organic layers were 
removed and transferred into another sterile 
tube, and evaporated to dryness under N2 (at 
40 °C). The dry residues were dissolved with 
0.2 ml of acetonitrile/water (50/50; v/v) and 
the solutions were transferred to glass micro-
vials using automatic pipettes with dispos-
able plastic tips. The vials were caped and 
placed into the autosampler (10 °C) racks.

High performance liquid chromatogra-
phy (HPLC) was performed on C18, 4 µm 
(100 × 2.1 mm i.d. (Jones Chromatography, 
Genesis, USA) at a flow rate of 0.45 ml/min 



Lodenafil carbonate Phase I study 903

and pressure of the system was ~ 120 bar. 
The mobile phase was acetonitrile/water 
(90/100; v/v) + 0.1% formic acid (Analysis 
Grade, J. T. Baker, USA). The column oper-
ated at room temperature. The temperature 
of the auto sampler operated at 10° ± 2 °C 
and the injection volume was 10 µl.

Typical standard retention times were 
1.1 ± 0.2 min for lodenafil carbonate, 0.8 ± 0.1 
min for lodenafil and 0.8 ± 0.1 min for the 
IS, and the total run-time was 2.4 min. The 
mass spectrometer (model API 4000, Sciex/
Applied Biosystems, Foster City, CA, USA) 
equipped with a turbospray source using a 
crossflow counter electrode, was run in posi-
tive mode (ES+) with multiple reaction moni-
toring (MRM). The mass spectrometer was 
set as follows: 1035.2 &gt; 487.1, 505.2 &gt; 487.0 
and 475.1 &gt; 283.2, for lodenafil carbonate, 
lodenafil and sildenafil, as the precursor ions 

and the respective product ions m/z. The limit 
of quantification in plasma was 0.5 ng/ml for 
both lodenafil carbonate and lodenafil.

Assay performance

A linear regression with a weighting 
index of 1/x^2 was performed on the peak 
area ratios of lodenafil carbonate and the 
internal standard versus the lodenafil car-
bonate concentrations of eight human plas-
ma standards (in duplicate) to generate a 
calibration curve. A linear regression with 
a weighting index of 1/x^2 was performed 
on the peak area ratios of lodenafil and 
the internal standard versus the lodenafil 
concentrations of the eight human plasma 
standards (in duplicate) to generate a cali-
bration curve.

Precision and accuracy: Within- and be-
tween-run precision was determined as the 
relative standard deviation, RSD (%) = 100 
(SD/M), and the accuracy as the percentage 
relative error, RE (%) = (E-T)(100/T), where 
M is the mean, SD is the standard deviation 
of M, E is the experimentally determined 
concentration and T is the theoretical con-
centration.

Pharmacokinetics

Individual plasma level-time curves were 
constructed and pharmacokinetic parameters 
were obtained according to a non-compart-
mental approach. The first-order terminal 
elimination rate constant (ke) was estimated by 
linear regression from the points describing the 
elimination phase in a log-linear plot, and the 
half-life (t1/2) was derived from this rate con-
stant (t1/2 = ln (2)/ke). The maximum plasma 
concentration (Cmax) and the time taken to 
achieve this concentration (tmax) were obtained 
directly from the curves. The areas under the 
lodenafil plasma concentration vs. time curves 
from time zero to the last detectable concentra-
tion (AUClast) were calculated by applying the 
linear trapezoid rule. Extrapolation of these ar-
eas to infinity (AUC?) was done by adding the 
value Clast/ke to the calculated AUClast (where 
Clast = the last detectable concentration). Clear-
ance (CL) was calculated by the formula dose/
AUC0-?. Volume of distribution (Vd) was cal-

Figure 2. Mean sitting systolic and diastolic blood 
pressures and sitting heart rates after lodenafil car-
bonate administration.



Mendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 904

culated by the formula Dose/Ke(AUC?). The 
software used included WinNonLin Profes-
sional Network Edition (Scientific Consulting, 
v. 3.0), Microsoft Excel (v. 7.0) and GraphPad 
Prism (v. 3.02).

Results

All biochemical parameters monitored 
presented no clinically relevant alterations 
during the Phase I study. No significant 
changes were observed in the laboratory 
exams and in the ECGs intra-study. Toler-
ance of both formulations (1 – 100 mg) was 
good and no significant adverse events were 
observed or reported. One volunteer had an 
adverse event (dysuria not related to therapy 
and classified as not serious) after the dis-
charge of the third confinement period dur-
ing the Phase I study. Two volunteers related 
spontaneous erections after administration 
of lodenafil carbonate (30 and 50 mg): one 
during the clinical evaluation for discharge 

of the study and one during the final clinical 
evaluation in the first period of confinement.

Laboratory tests after administration of 
lodenafil carbonate are shown in Table 4. 
Blood pressure and heart rate were assessed 
for 24 h after treatment with lodenafil car-
bonate (Figure 2) (Table 5).

The mean lodenafil plasma concentrations 
vs. time profiles after testing single oral doses 
of lodenafil carbonate in males are shown in 
Figure 1. Calculated mean pharmacokinetic 
parameters of lodenafil are given in Table 3.

The method was linear for lodenafil car-
bonate and lodenafil concentrations from 0.5 
to 2,000 ng/ml. No significant matrix effect 
was observed. The limit of quantification 
(LOQ), defined as the lowest concentration 
at which both the precision and accuracy 
were &amp;lt;20%, was 0.5 ng/ml for lodenafil 
carbonate and lodenafil. The within- and 
between-run precision and accuracy for the 
quality controls are summarized in Table 2.

Table 5. Mean sitting systolic and diastolic blood pressures and mean heart rates after lodenafil carbon-
ate administration.

Time Mean diastolic blood 
pressures

Mean systolic blood 
pressures

Mean heart rate

Mean SD Min Max Mean SD Min Max Mean SD Min Max
0 71 7 56 89 113 8 91 132 63 7 41 86
1 70 7 54 93 113 8 86 134 59 7 42 77
2 72 8 52 96 114 8 88 134 61 8 43 85
3 69 9 45 99 115 8 88 145 65 10 45 100
4 68 9 41 93 115 10 95 138 66 10 43 107
5 71 10 44 97 118 9 89 143 72 11 48 107
6 65 9 40 89 113 10 77 135 67 8 49 85
7 66 10 40 96 112 9 85 133 68 10 46 99
8 67 9 40 93 112 10 90 135 66 10 46 92
9 65 11 43 86 112 16 90 140 65 12 46 97
10 66 9 43 88 112 11 84 143 68 10 48 92
11 68 11 44 90 114 10 86 138 65 10 48 92
12 74 10 50 98 117 11 94 149 70 14 47 111
13 70 11 44 95 117 10 93 146 69 11 47 104
14 69 10 44 89 116 10 82 143 70 10 49 102
15 64 10 46 94 112 11 91 142 66 10 46 99
16 65 8 46 84 113 10 83 144 67 11 45 115
17 62 9 44 80 110 10 84 135 64 10 44 89
18 63 10 41 89 110 11 86 136 62 11 42 98
19 63 8 43 81 108 8 87 127 62 13 42 138
20 65 8 45 88 109 10 88 133 62 10 42 87
21 62 10 43 91 105 11 83 142 60 10 46 105
22 62 10 40 84 105 12 79 132 59 9 41 82
23 63 11 42 91 106 11 74 127 61 11 39 98
24 73 8 54 91 116 7 98 132 70 9 49 91



Lodenafil carbonate Phase I study 905

Discussion

High-performance liquid chromatography 
(HPLC) coupled with tandem mass spec-
trometry (LC-MS-MS) in animal and hu-
man plasma has been used for lodenafil and/
or lodenafil carbonate quantification [1, 4]. 
However, no full validation method has been 
previously published for lodenafil and lode-
nafil carbonate quantification. Our method 
employed sildenafil as internal standard in-
stead of theophylline, having a shorter reten-
tion time of 1.1 min for lodenafil carbonate 
and 0.8 min for lodenafil. The limit of quan-
tification (0.5 ng/ml) was adequate for phar-
macokinetic evaluation of lodenafil carbon-
ate and lodenafil.

The results obtained following oral ad-
ministration of lodenafil carbonate in healthy 
male volunteers show that lodenafil carbon-
ate acts as a prodrug when given orally, since 
no quantifiable lodefanil carbonate concen-
tration has been detected in the systemic 
circulation. Similar results were observed in 
male beagles following oral administration 
of lodenafil carbonate [1].

The adverse event of dysuria was evalu-
ated as not serious since the volunteer spon-
taneously recovered and only reported in the 
medical final evaluation.

After the oral administration of the lode-
nafil carbonate 80 mg tablets to the volun-
teers, the tmax (1.6 h) and t1/2 (3.3 h) were 
similar to the reported in the literature (tmax: 
1.2 – 1.5 h; t1/2: 2.4 – 3 h) [2]. The Cmax 
(17.62 ng/ml) and AUC (42.80 h×ng/ml) 
values were different to those reported in the 
literature (Cmax 158 ng/ml; AUC 528 h×ng/
ml) for a lodenafil carbonate tablet (dose 160 
mg; two tablets of 80 mg) formulation [2].

As shown in Table 3, the pk parameters 
calculated for 1 mg are not reliable due to 
low plasma lodenafil after a dose of 1 mg. 
The major differences for t1/2, Cl and Vd 
over the dose range can be explained by the 
low number (n = 3 to 1 mg; n = 6 to 2 mg and 
n = 9 between 3 mg and 100 mg) of volunteer 
per dose and by the variability inter-subject.

The mean lodenafil pharmacokinetic pa-
rameters for tmax (1.6 ± 0.4 h) was similar 
to the PDE5 (sildenafil 1 h, tadalafil 1.8 h, 
vardenafil 0.75 h, udenafil 1 h, and avanafil 
0.33 h). The mean lodenafil pharmacokinetic 
parameters for t1/2 (3.3 h) were similar to the 

sildenafil and vardenafil (sildenafil 2.76 h, 
vardenafil 2.63 h, avanafil 5.36 h, udenafil 
11 h and tadalafil 21.1 h) [6, 7, 8, 9, 10].

No serious adverse events were ob-
served, and none of the subjects discontin-
ued the study because of lack of tolerance. 
As shown in Table 4 and Table 5, the AMAP 
measurements and clinical tests revealed no 
significant alteration even at a higher dose. 
The lodenafil carbonate presented good tol-
erance and safety for healthy male volunteers 
in Phase I study. The recommended dose of 
80 mg was used in following trials and it is 
the commercial formulation dose marketed 
in Brazil.

Acknowledgments

The Phase I trial was sponsored by Cris-
tália Produtos Químicos e Farmacêuticos 
Ltda, Itapira, Brazil. AcademicEnglishSolu-
tions.com revised the English. Gilberto De 
Nucci is a visiting Professor at the Depart-
ment of Clinical Pharmacy, King Saud Uni-
versity, Riyadh, Saudi Arabia.

References
[1] Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, 

Antunes E, De Nucci G. Pharmacological charac-
terization of a novel phosphodiesterase type 5 
(PDE5) inhibitor lodenafil carbonate on human and 
rabbit corpus cavernosum. Eur J Pharmacol. 2008; 
591: 189-195. doi:10.1016/j.ejphar.2008.06.055 
PubMed

[2] Silva AC, Toffoletto O, Lucio LA, Santos PF, 
Afiune JB, Massud Filho J, Tufik S. [Cardiovascular 
repercussion of lodenafil carbonate, a new PDE5 
inhibitor, with and without alcohol consumption]. 
Arq Bras Cardiol. 2010; 94: 150-156, 160-167, 
152-158. PubMed

[3] Glina S, Toscano I, Gomatzky C, de Góes PM, 
Júnior AN, Claro JF, Pagani E. Efficacy and 
tolerability of lodenafil carbonate for oral therapy 
in erectile dysfunction: a phase II clinical trial. J 
Sex Med. 2009; 6: 553-557. 
doi:10.1111/j.1743-6109.2008.01079.x PubMed

[4] Glina S, Fonseca GN, Bertero EB, Damião R, 
Rocha LC, Jardim CR, Cairoli CE, Teloken C, 
Torres LO, Faria GE, da Silva MB, Pagani E. 
Efficacy and tolerability of lodenafil carbonate for 
oral therapy of erectile dysfunction: a phase III 
clinical trial. J Sex Med. 2010; 7: 1928-1936. 
doi:10.1111/j.1743-6109.2010.01711.x PubMed

[5] Diário Oficial da União – DOU. http://ww w.in.go 
v.br/imprensa/visualiza/index.jsp?jo rna l = 1010&amp;amp; 
pagina = 22&amp;amp;data = 22/10/2007.

[6] Stavros F, Kramer WG, Wilkins MR. The effects 
of sitaxentan on sildenafil pharmacokinetics and 

http://dx.doi.org/10.1016/j.ejphar.2008.06.055
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18593576&amp;amp;dopt=Abstract
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18593576&amp;amp;dopt=Abstract
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20428608&amp;amp;dopt=Abstract
http://dx.doi.org/10.1111/j.1743-6109.2008.01079.x
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19040623&amp;amp;dopt=Abstract
http://dx.doi.org/10.1111/j.1743-6109.2010.01711.x
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20214718&amp;amp;dopt=Abstract


Mendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 906

pharmacodynamics in healthy subjects. Br J Clin 
Pharmacol. 2010; 69: 23-26. 
doi:10.1111/j.1365-2125.2009.03541.x PubMed

[7] Garraffo R, Lavrut T, Ferrando S, Durant J, 
Rouyrre N, MacGregor TR, Sabo JP, Dellamonica 
P. Effect of tipranavir/ritonavir combination on the 
pharmacokinetics of tadalafil in healthy volunteers. 
J Clin Pharmacol. 2011; 51: 1071-1078. 
doi:10.1177/0091270010379808 PubMed

[8] Berry B, Altman P, Rowe J, Vaisman J. Com pa rison 
of Pharmacokinetics of Vardenafil Administered 
Using an Ultrasonic Nebulizer for Inhalation vs. a 
Single 10-mg Oral Tablet. J Sex Med. 2009; Jul 
28. [Epub ahead of print]. 
doi:10.1111/j.1743-6109.2009.01403.x PubMed

[9] Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee 
SW, Paick JS, Ahn TY, Min KS, Park K, Park JK. 
Efficacy and safety of once-daily dosing of 
udenafil in the treatment of erectile dysfunction: 
results of a multicenter, randomized, double-
blind, placebo-controlled trial. Eur Urol. 2011; 
60: 380-387.

[10] Jung J, Choi S, Cho SH, Ghim JL, Hwang A, Kim 
U, Kim BS, Koguchi A, Miyoshi S, Okabe H, Bae 
KS, Lim HS. Tolerability and pharmacokinetics of 
avanafil, a phosphodiesterase type 5 inhibitor: a 
single- and multiple-dose, double-blind, randomized, 
placebo-controlled, dose-escalation study in healthy 
Korean male volunteers. Clin Ther. 2010; 32: 
1178-1187. doi:10.1016/j.clinthera.2010.06.011 
PubMed

[11] Report of the Dietary Guidelines Advisory Com­
mittee on the Dietary Guidelines for Americans. 
2000, http://www.health.gov/diet aryguidelines/ 
dgac/pdf/dgac_ful.pdf

[12] Limin M, Johnsen N, Hellstrom WJ. Avanafil, a 
new rapid-onset phosphodiesterase 5 inhibitor for 
the treatment of erectile dysfunction. Expert Opin 
Investig Drugs. 2010; 19: 1427-1437. doi:10.151
7/13543784.2010.518955 PubMed

[13] De Nucci G. Estudo clínico fase I do carbonato de 
lodenafila em voluntários sadios do sexo masculino. 
Int Braz J Urol. 2007; 33 (Suppl 2): 148.

http://dx.doi.org/10.1111/j.1365-2125.2009.03541.x
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20078609&amp;amp;dopt=Abstract
http://dx.doi.org/10.1177/0091270010379808
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21209236&amp;amp;dopt=Abstract
http://dx.doi.org/10.1111/j.1743-6109.2009.01403.x
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19656275&amp;amp;dopt=Abstract
http://dx.doi.org/10.1016/j.clinthera.2010.06.011
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20637970&amp;amp;dopt=Abstract
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20637970&amp;amp;dopt=Abstract
http://dx.doi.org/10.1517/13543784.2010.518955
http://dx.doi.org/10.1517/13543784.2010.518955
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20939743&amp;amp;dopt=Abstract


 

 73  
 

ANEXO IV 

Outras publicações durante o período de doutorado 

 

Curr Drug Metab. 2005 Dec;6(6):519-29. 

Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-

dihydroergocristine in human plasma. 

Bicalho B, Guzzo GC, Lilla S, Dos Santos HO, Mendes GD, Caliendo G, Perissutti E, Aiello 

A, Luciano P, Santagada V, Pereira AS, De Nucci G. 

Galeno Research Unit, R. Latino Coelho 1301, Campinas, SP, Brazil. 

Abstract 

Dihydroergocristine (DHEC) is a semi-synthetic drug mainly used for age-related cognitive 

impairment. In this study, its major metabolite 8'-hydroxy-dihydroergocristine (8'-OH-DHEC) 

was produced in incubates of a bovine liver preparation using dihydroergocristine mesylate 

(DHECM) as substrate. Purification was achieved by flash silica gel column and reverse 

phase liquid chromatographies, and identification was based on accurate molecular mass 

measurements, mass fragmentation spectra and NMR ((1)H/(13)C) chemical shifts. By using 

the substance produced in vitro, a fast, sensitive, specific and robust LC/MS/MS method for 

the simultaneous determination of DHEC and its major metabolite in human plasma was 

developed and validated. Bromocriptine was used as internal standard and limits of 

quantification for DHEC and 8'-OH-DHEC were 10 pg/ml and 20 pg/ml, respectively. 

Pharmacokinetic parameters were investigated on 12 male healthy volunteers to whom a 

single dose of 18 mg DHECM was administered in tablets (Iskevert). The peak of DHEC was 

0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and 

the terminal elimination half-life 3.50 +/- 2.27 h. The peak of 8'-OH-DHEC was 5.63 +/- 3.34 

adriana.yamaguchi
Texto digitado



 

 74  
 

microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal 

elimination half-life 3.90 +/- 1.07 h. Dosing of 18 mg DHECM was well tolerated, causing no 

adverse events. 

PMID: 16379666 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 75  
 

Arzneimittelforschung. 2007;57(9):582-90. 

Comparative bioavailability study with two amiodarone tablet formulations 

administered with and without food in healthy subjects. 

dos Santos Filho HO, Ilha JO, Silva LC, Borges A, Mendes GD, De Nucci G. 

Cartesius Analytical Unit, Department of Pharmacology, Institute of Biomedical Sciences, 

University of São Paulo, São Paulo, SP, Brazil. 

Abstract 

OBJECTIVE:  The aim was to assess the comparative bioavailability of two formulations 

(200 mg tablet) of amiodarone (CAS 19774-82-4) in healthy volunteers of both sexes, with 

and without food. 

METHODS:  The study was conducted using an open, randomized, two-period crossover 

design with a 3-week washout interval, in two groups, with and without food. Plasma samples 

were obtained for up to 240 h post dose. Plasma amiodarone concentrations were analyzed by 

liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) with positive ion 

electrospray ionization using multiple reactions monitoring (MRM). From the amiodarone 

plasma concentration vs. time curves, the following pharmacokinetic parameters were 

obtained, with and without food: AUC(last), AUC(inf), AUC(0-240h), AUC(0-72h) and 

C(max). 

RESULTS:  The limit of quantification was 1 ng/mL for plasma amiodarone analysis. The 

geometric mean and 90% confidence interval CI of Test/Reference percent ratios were, 

without and with food, respectively: 107.61 (92.73-124.89) and 100.6 (94.1-107.5) for 

C(max), 107.05 (95.88-119.51) and 100.2 (96.0-104.7) for AUC(last), 107.27 (95.78-120.15) 

and 100.8 (97.0-104.8) for AUC(0-72h), 106.76 (95.84-118.94) and 100.2 (96.0-104.7) for 

AUC(0-240h) and AUC(inf) 105.15 (94.18-117.41) and 100.7 (96.6-105.0). 



 

 76  
 

CONCLUSION: Since the 90% CI for AUC(0-72) and C(max) ratios were within the 80-

125% interval proposed by the US FDA, it was concluded that the amiodarone 200 mg tablet 

(test formulation) with and without food was bioequivalent to the reference 200 mg tablet for 

both the rate and extent of absorption. 

PMID:17966757 

 

 

 




</field>
	</doc>
</add>